Contemporary update of prostate cancer staging nomog millennium

Urology

58, 843-848

DOI: 10.1016/s0090-4295(01)01441-8

Citation Report

#	Article	IF	Citations
1	ecancermedicalscience. Ecancermedicalscience, 2014, 8, 458.	0.6	6
2	RE: HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED CANCER. Journal of Urology, 2001, 166, 2321-2322.	0.2	5
3	Pathology of prostate cancer. , 2002, , 3-17.		0
4	What your patient needs to know about Prostate Cancer. Nursing, 2002, 32, 36-43.	0.2	2
5	Prostate cancer: management and controversies. British Journal of Hospital Medicine, 2002, 63, 465-470.	0.3	0
6	Prediction of Progression: Nomograms of Clinical Utility. Clinical Prostate Cancer, 2002, 1, 90-96.	2.1	64
7	The Management of Localized or Locally Advanced Prostate Cancer. American Journal of Cancer, 2002, 1, 387-396.	0.4	1
8	Gleason Score 7 Prostate Cancer on Needle Biopsy: Is the Prognostic Difference in Gleason Scores 4 3 and 3 4 Independent of the Number of Involved Cores?. Journal of Urology, 2002, 167, 2440-2442.	0.2	90
9	Suppression of Tumor Recurrence and Metastasis by a Combination of the PHSCN Sequence and the Antiangiogenic Compound Tetrathiomolybdate in Prostate Carcinoma. Neoplasia, 2002, 4, 373-379.	2.3	63
11	Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men. Urology, 2002, 60, 18-23.	0.5	12
12	Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. Urology, 2002, 60, 10-17.	0.5	21
13	Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. Urology, 2002, 60, 1034-1039.	0.5	29
14	Comparison of Logistic Regression and Neural Net Modeling for Prediction of Prostate Cancer Pathologic Stage. Clinical Chemistry, 2002, 48, 1828-1834.	1.5	33
15	Predicting Prostate-Specific Antigen Recurrence Established: Now, Who Will Survive?. Journal of Clinical Oncology, 2002, 20, 3188-3190.	0.8	11
16	Whatâ€™s new in urology. Journal of the American College of Surgeons, 2002, 195, 663-674.	0.2	4
17	Urinary Continence and Erectile Function: A Prospective Evaluation of Functional Results after Radical Laparoscopic Prostatectomy. European Urology, 2002, 42, 338-343.	0.9	108
19	Gleason score on biopsy: is it reliable for predicting the final grade on pathology?. BJU International, 2002, 90, 694-698.	1.3	85
21	Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume?. International Journal of Radiation Oncology Biology Physics, 2002, 54, 686-697.	0.4	132

#	Article	IF	Citations
22	Outcome and complications of radical prostatectomy in patients with PSA <10â€...ng/ml: comparison between the retropubic, perineal and laparoscopic approach. Prostate Cancer and Prostatic Diseases, 2002, 5, 285-290.	2.0	40
23	Pathology of prostate cancer. Cancer and Metastasis Reviews, 2002, 21, 381-396.	2.7	13
24	Conformal Radiotherapy to the Prostate: are Bigger Fields Better?. Clinical Oncology, 2002, 14, 296-297.	0.6	2
26	The evolving role of pelvic radiation therapy. Seminars in Radiation Oncology, 2003, 13, 109-120.	1.0	15
27	Prognostic Significance of Tumor Volume after Radical Prostatectomy: A Multivariate Analysis of Pathological Prognostic Factors. European Urology, 2003, 43, 39-44.	0.9	89
28	Combined Reporting of Cancer Control and Functional Results of Radical Prostatectomy. European Urology, 2003, 44, 656-660.	0.9	79
29	Predicting clinical end points: treatment nomograms in prostate cancer. Seminars in Oncology, 2003, 30, 567-586.	0.8	33
30	Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma. Cancer, 2003, 97, 969-978.	2.0	29
31	Reduction of dose delivered to the rectum and bulb of the penis using MRI delineation for radiotherapy of the prostate. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1269-1279.	0.4	95
32	Topographic anatomy of the male perineal structures with special reference to perineal approaches for radical prostatectomy. International Journal of Urology, 2003, 10, 141-148.	0.5	36
33	Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?. BJU International, 2003, 91, 23-29.	1.3	38
34	Differences in biopsy features between prostate cancers located in the transition and peripheral zone. BJU International, 2003, 91, 477-481.	1.3	34
35	Partin tables: past and present. BJU International, 2003, 92, 7-11.	1.3	21
36	Watchful waiting in prostate cancer: review and policy proposals. BJU International, 2003, 92, 851-859.	1.3	15
37	Biochemical recurrence following radical prostatectomy: A comparison between prostate cancers located in different anatomical zones. Prostate, 2003, 55, 48-54.	1.2	39
38	Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. Prostate, 2003, 56, 23-29.	1.2	41
39	Applications of Fourier transform infrared microspectroscopy in studies of benign prostate and prostate cancer. A pilot study. Journal of Pathology, 2003, 201, 99-108.	2.1	155
40	Is there a difference in outcome after radical prostatectomy between patients with biopsy Gleason sums 4, 5, and 6? results from the SEARCH database. Prostate Cancer and Prostatic Diseases, 2003, 6, 261-265.	2.0	8

#	Article	IF	Citations
41	Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: Year of treatment an independent predictor of outcome. International Journal of Radiation Oncology Biology Physics, 2003, 57, 629-634.	0.4	41
42	A Nomogram to Predict Seminal Vesicle Invasion by the Extent and Location of Cancer in Systematic Biopsy Results. Journal of Urology, 2003, 170, 1203-1208.	0.2	119
43	Radical Endoscopic Assisted Perineal Prostatectomy. Journal of Urology, 2003, 170, 170-173.	0.2	13
44	CÃ¡ncer de prÃ³stata. Medicine, 2003, 8, 6159-6168.	0.0	0
45	Imaging clinically localized prostate cancer. Urologic Clinics of North America, 2003, 30, 279-293.	0.8	77
47	An Artificial Neural Network for Prostate Cancer Staging when Serum Prostate Specific Antigen is 10 NG./ML. or Less. Journal of Urology, 2003, 169, 1724-1728.	0.2	34
48	Caso clÃnico A propÃ³sito de dos casos con elevaciÃ³n leve e intensa de PSA. Medicine, 2003, 8, 6195-6198.	0.0	0
49	Introducing a prognostic score for pretherapeutic assessment of seminal vesicle invasion in patients with clinically localized prostate cancer. Radiotherapy and Oncology, 2003, 67, 313-319.	0.3	13
50	Contemporary management of prostate cancer: a practice survey of Ontario genitourinary radiation oncologists. Radiotherapy and Oncology, 2003, 69, 63-72.	0.3	5
51	Clinical Strategies in the Management of Biochemical Recurrence After Radical Prostatectomy. Clinical Prostate Cancer, 2003, 2, 160-166.	2.1	6
52	Time Trends in Clinical Risk Stratification for Prostate Cancer: Implications for Outcomes (Data From) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.2	270
53	Image-Guided Diagnosis and Treatment of Cancer. , 2003, , .		6
54	Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer. Urology, 2003, 62, 1058-1062.	0.5	11
55	Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer. Urology, 2003, 62, 9-18.	0.5	72
56	Evaluation of the interobserver reproducibility of gleason grading of prostatic adenocarcinoma using tissue microarrays. Human Pathology, 2003, 34, 444-449.	1.1	40
57	Preoperative cardiopulmonary risk assessment as predictor of early noncancer and overall mortality after radical prostatectomy. Urology, 2003, 61, 596-600.	0.5	26
58	Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening. Urology, 2003, 62, 70-74.	0.5	38
59	Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy?. Urology, 2003, 62, 79-85.	0.5	55

#	Article	IF	Citations
60	Radical retropubic versus laparoscopic prostatectomy: a prospective comparison of functional outcome. Urology, 2003, 62, 292-297.	0.5	179
61	Rare case of metastatic prostate adenocarcinoma to the pituitary. Urology, 2003, 62, 352.	0.5	12
62	Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression. Urology, 2003, 62, 304-309.	0.5	61
63	Probability of biochemical recurrence by analysis of pathologic stage, gleason score, and margin status for localized prostate cancer. Urology, 2003, 62, 866-871.	0.5	75
64	Early prostate cancer: clinical decision-making. Lancet, The, 2003, 361, 1045-1053.	6.3	195
65	Pathologic features the urologist should expect on a prostate biopsy. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 153-161.	0.8	11
66	Biochemical staging of prostate cancer. Urologic Clinics of North America, 2003, 30, 263-277.	0.8	33
67	Looking Beyond Morphology: Cancer Gene Expression Profiling Using DNA Microarrays. Cancer Investigation, 2003, 21, 937-949.	0.6	45
68	Management of Highâ€Risk Populations with Locally Advanced Prostate Cancer. Oncologist, 2003, 8, 259-269.	1.9	34
70	The Addition of Interleukin-6 Soluble Receptor and Transforming Growth Factor Beta1Improves a Preoperative Nomogram for Predicting Biochemical Progression in Patients With Clinically Localized Prostate Cancer. Journal of Clinical Oncology, 2003, 21, 3573-3579.	0.8	211
71	Radical Prostatectomy for Prostate Cancer Patients with Prostate-specific Antigen >20 ng/ml. Japanese Journal of Clinical Oncology, 2003, 33, 574-579.	0.6	7
72	Prognostic Significance of Visible Lesions on Transrectal Ultrasound in Impalpable Prostate Cancers: Implications for Staging. Journal of Clinical Oncology, 2003, 21, 2860-2868.	0.8	26
73	Quality-of-Care Indicators for Early-Stage Prostate Cancer. Journal of Clinical Oncology, 2003, 21, 1928-1936.	0.8	119
74	Freeâ€toâ€total prostateâ€specific antigen ratio as a predictor of nonâ€organâ€confined prostate cancer (stage) Tj ETQq1 1 0.78431	1.4	10
75	Introducing a new, simple scoring system to evaluate oncological and functional outcome after radical prostatectomy. Scandinavian Journal of Urology and Nephrology, 2003, 37, 392-395.	1.4	5
76	Prostate cancer update. Current Opinion in Oncology, 2003, 15, 217-221.	1.1	26
77	Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Current Opinion in Urology, 2003, 13, 111-116.	0.9	190
79	Understanding the Prostate Literature: The Need for a Multi-Disciplined Approach. Journal of the National Comprehensive Cancer Network: JNCCN, 2004, 2, 181-182.	2.3	1

#	Article	IF	Citations
80	Prostate Cancer: Detection of Extracapsular Extension by Genitourinary and General Body Radiologists at MR Imaging. Radiology, 2004, 232, 140-146.	3.6	166
81	Progress toward Identifying Aggressive Prostate Cancer. New England Journal of Medicine, 2004, 351, 180-181.	13.9	10
83	Prostate Cancer: Incremental Value of Endorectal MR Imaging Findings for Prediction of Extracapsular Extension. Radiology, 2004, 232, 133-139.	3.6	205
84	High Levels of Circulating Insulin-Like Growth Factor-I Increase Prostate Cancer Risk: A Prospective Study in a Population-Based Nonscreened Cohort. Journal of Clinical Oncology, 2004, 22, 3104-3112.	0.8	132
85	Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate Cancer. Clinical Cancer Research, 2004, 10, 3927-3933.	3.2	54
86	High Levels of Phosphorylated Form of Akt-1 in Prostate Cancer and Non-Neoplastic Prostate Tissues Are Strong Predictors of Biochemical Recurrence. Clinical Cancer Research, 2004, 10, 6572-6578.	3.2	186
87	Radiation Therapy and Androgen Suppression as Treatment for Clinically Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2004, 292, 864.	3.8	9
88	Prostate Cancer Localization with Endorectal MR Imaging and MR Spectroscopic Imaging: Effect of Clinical Data on Reader Accuracy. Radiology, 2004, 230, 215-220.	3.6	96
89	Combining longitudinal studies of PSA. Biostatistics, 2004, 5, 483-500.	0.9	32
90	A low incidence of positive surgical margins in prostate cancer at high risk of extracapsular extension after a modified anterograde radical prostatectomy. BJU International, 2004, 93, 279-283.	1.3	18
91	Open versus laparoscopic radical prostatectomy: Part II. BJU International, 2004, 94, 244-250.	1.3	57
92	Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results. BJU International, 2004, 94, 805-811.	1.3	36
93	The total percentage of biopsy cores with cancer improves the prediction of pathological stage after radical prostatectomy. BJU International, 2004, 94, 812-815.	1.3	11
94	Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer. International Journal of Urology, 2004, 11, 218-224.	0.5	16
95	Transrectal ultrasound-guided transperineal 14-core systematic biopsy detects apico-anterior cancer foci of T1c prostate cancer. International Journal of Urology, 2004, 11, 613-618.	0.5	53
96	Diagnostic Significance of PSA Density Adjusted by Transition Zone Volume in Males with PSA Levels between 2 and 4ng/ml. European Urology, 2004, 45, 92-97.	0.9	15
97	Comparison of adjuvant versus salvage radiotherapy policies for postprostatectomy radiotherapy. International Journal of Radiation Oncology Biology Physics, 2004, 59, 329-340.	0.4	52
98	Shared decision-making?Results from an interdisciplinary consulting service for prostate cancer. World Journal of Urology, 2004, 22, 441-448.	1.2	14

#	Article	IF	Citations
99	Management of patients with an increasing prostate-specific antigen after radical prostatectomy. Current Prostate Reports, 2004, 2, 12-20.	0.1	0
100	Management of patients with an increasing prostate-specific antigen after radical prostatectomy. Current Urology Reports, 2004, 5, 179-187.	1.0	20
101	Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer. Current Urology Reports, 2004, 5, 231-240.	1.0	12
102	Decreased stromal expression and increased epithelial expression of WFDC1/ps20 in prostate cancer is associated with reduced recurrence-free survival. Prostate, 2004, 61, 182-191.	1.2	32
103	Surgical margin and gleason score as predictors of postoperative recurrence in prostate cancer with or without chromosome 8p allelic imbalance. Prostate, 2004, 61, 81-91.	1.2	9
104	Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organization. Cancer, 2004, 100, 300-307.	2.0	21
105	The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer, 2004, 100, 2655-2663.	2.0	181
106	Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer, 2004, 101, 748-753.	2.0	24
107	MRI-guided HDR prostate brachytherapy in standard 1.5T scanner. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1414-1423.	0.4	139
108	Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with 192ir brachytherapy: A prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25. International Journal of Radiation Oncology Biology Physics, 2004, 60, 51-59.	0.4	23
110	Expression of the Survivin Gene in Prostate Cancer: Correlation With Clinicopathological Characteristics, Proliferative Activity and Apoptosis. Journal of Urology, 2004, 171, 1855-1860.	0.2	87
111	QUANTITATIVE GSTP1 METHYLATION LEVELS CORRELATE WITH GLEASON GRADE AND TUMOR VOLUME IN PROSTATE NEEDLE BIOPSIES. Journal of Urology, 2004, 171, 2195-2198.	0.2	48
112	Comparison of Accuracy Between the Partin Tables Of 1997 and 2001 to Predict Final Pathological Stage in Clinically Localized Prostate Cancer. Journal of Urology, 2004, 171, 177-181.	0.2	67
113	Do Concerns About More Advanced Pathological Features Increase the Likelihood of Neurovascular Bundle Resection in Black Men Undergoing Radical Prostatectomy?. Journal of Urology, 2004, 171, 700-702.	0.2	1
114	Predicting the Presence and Side of Extracapsular Extension: A Nomogram for Staging Prostate Cancer. Journal of Urology, 2004, 171, 1844-1849.	0.2	277
115	THE IMPACT OF SURGICAL APPROACH (NERVE BUNDLE PRESERVATION VERSUS WIDE LOCAL EXCISION) ON SURGICAL MARGINS AND BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 2004, 172, 1328-1332.	0.2	153
116	PREOPERATIVE MODEL FOR PREDICTING PROSTATE SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY USING PERCENT OF BIOPSY TISSUE WITH CANCER, BIOPSY GLEASON GRADE AND SERUM PROSTATE SPECIFIC ANTIGEN. Journal of Urology, 2004, 171, 2215-2220.	0.2	48
117	VALIDATION OF THE KATTAN PREOPERATIVE NOMOGRAM FOR PROSTATE CANCER RECURRENCE USING A COMMUNITY BASED COHORT: RESULTS FROM CANCER OF THE PROSTATE STRATEGIC UROLOGICAL RESEARCH ENDEAVOR (CAPSURE). Journal of Urology, 2004, 171, 2255-2259.	0.2	100

#	Article	IF	Citations
118	Management of Prostate Cancer. , 2004, , .		2
119	Combining external beam radiotherapy with prostate brachytherapy: Issues and rationale. Urology, 2004, 64, 855-861.	0.5	7
120	The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 307-312.	0.8	57
121	The role of lymphadenectomy in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2004, 22, 198-202.	0.8	24
123	Is Seminal Vesicle Ablation Mandatory for All Patients Undergoing Radical Prostatectomy?. European Urology, 2004, 46, 42-49.	0.9	45
125	Permanent Interstitial Brachytherapy for Clinically Organ-Confined High-Grade Prostate Cancer With a Pretreatment PSA < 20 ng/mL. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 611-615.	0.6	12
126	Prognostic Significance of Percent Positive Biopsies in Clinically Organ Confined Prostate Cancer Treated with Permanent Prostate Brachytherapy With or Without Supplemental External Beam Radiation. Cancer Journal (Sudbury, Mass), 2004, 10, 54-60.	1.0	18
127	Update of staging and risk assessment for prostate cancer patients. Current Opinion in Urology, 2004, 14, 163-170.	0.9	11
128	The Impact of Primary Gleason Grade on Biochemical Outcome Following Brachytherapy for Hormone-Naive Gleason Score 7 Prostate Cancer. Cancer Journal (Sudbury, Mass), 2005, 11, 234-240.	1.0	12
129	When and how to use informatics tools in caring for urologic patients. Nature Reviews Urology, 2005, 2, 183-190.	1.4	32
130	Quality assurance of HDR prostate plans: Program implementation at a community hospital. Medical Dosimetry, 2005, 30, 243-248.	0.4	1
131	Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2005, 61, 32-43.	0.4	91
132	Quantification of shape variation of prostate and seminal vesicles during external beam radiotherapy. International Journal of Radiation Oncology Biology Physics, 2005, 61, 228-238.	0.4	327
133	Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. International Journal of Radiation Oncology Biology Physics, 2005, 63, 795-799.	0.4	10
134	Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1474-1482.	0.4	42
135	Variability of prostate brachytherapy preimplant dosimetry: A multi-institutional analysis. Brachytherapy, 2005, 4, 241-251.	0.2	49
136	Imaging for Prostate Cancer. Clinical Oncology, 2005, 17, 553-559.	0.6	21
137	Surgical margin status after radical retropubic prostatectomy. BJU International, 2005, 95, 281-284.	1.3	14

#	Article	IF	Citations
138	Anatomical radical retropubic prostatectomy: 'curtain dissection' of the neurovascular bundle. BJU International, 2005, 95, 1226-1231.	1.3	156
139	Inguinal hernia repair with polypropylene mesh during radical retropubic prostatectomy: an easy and practical approach. BJU International, 2005, 96, 330-333.	1.3	23
140	The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels. BJU International, 2005, 96, 995-998.	1.3	30
141	Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU International, 2005, 96, 41-46.	1.3	47
142	Is a limited lymphadenectomy targeting obturator nodes alone an adequate procedure for Japanese men undergoing radical prostatectomy?. International Journal of Urology, 2005, 12, 739-744.	0.5	4
143	Is There a Need for Pelvic Lymph Node Dissection in Low Risk Prostate Cancer Patients Prior to Definitive Local Therapy?. European Urology, 2005, 47, 45-51.	0.9	43
144	Validation of 2001 Partin Tables in Turkey: A Multicenter Study. European Urology, 2005, 47, 185-189.	0.9	20
145	Prognostic Parameters Other Than Gleason Score for the Daily Evaluation of Prostate Cancer in Needle Biopsy. European Urology, 2005, 48, 566-571.	0.9	18
146	What Constitutes High-Risk Locally Advanced Prostate Cancer?. Clinical Genitourinary Cancer, 2005, 4, 193-196.	0.9	1
147	Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer, 2005, 5, 91.	1.1	32
148	Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. Cancer, 2005, 103, 708-716.	2.0	30
149	Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes. Cancer Chemotherapy and Pharmacology, 2005, 56, 69-77.	1.1	3
151	Local and systemic therapy for patients with metastatic prostate cancer: Should the primary tumor be treated?. Current Prostate Reports, 2005, 3, 153-159.	0.1	1
152	Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer. Current Prostate Reports, 2005, 3, 11-20.	0.1	0
153	Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?. Current Urology Reports, 2005, 6, 183-189.	1.0	11
154	Prostate Cancer in the Elderly. International Urology and Nephrology, 2005, 37, 797-806.	0.6	7
155	Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate, 2005, 62, 140-147.	1.2	155
156	Use of thymosin Î²15 as a urinary biomarker in human prostate cancer. Prostate, 2005, 64, 116-127.	1.2	28

#	Article	IF	Citations
157	Clinically Localized (Stage T1a-T2c) Adenocarcinoma of the Prostate: Surgical Management and Prognosis. , 2005, , 465-476.		0
158	Anatomic Nerve-Sparing Radical Retropubic Prostatectomy. , 2005, , 514-527.		0
159	Surgical Treatment of Prostate Cancer. , 2005, , 69-76.		0
160	Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer. Prostate Cancer and Prostatic Diseases, 2005, 8, 248-252.	2.0	10
161	Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: A prospective assessment of acute and late treatment toxicity. Acta OncolÃ³gica, 2005, 44, 633-643.	0.8	13
162	The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer and Prostatic Diseases, 2005, 8, 22-30.	2.0	120
163	Case study: management of lymph node-positive disease detected at radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2005, 8, 287-289.	2.0	0
164	Sociodemographic factors associated with postprostatectomy radiotherapy. Prostate Cancer and Prostatic Diseases, 2005, 8, 184-188.	2.0	12
165	Radiotherapy in the Management of Clinically Localized Prostate Cancer: Evolving Standards, Consensus, Controversies and New Directions. Journal of Clinical Oncology, 2005, 23, 8176-8185.	0.8	50
166	The evaluation and staging of clinically localized prostate cancer. Nature Reviews Urology, 2005, 2, 356-357.	1.4	4
167	Radical Prostatectomy versus Watchful Waiting. New England Journal of Medicine, 2005, 353, 1298-1300.	13.9	9
168	Multigene Methylation Analysis for Detection and Staging of Prostate Cancer. Clinical Cancer Research, 2005, 11, 6582-6588.	3.2	106
169	Implications of the Prostate Cancer Prevention Trial: A Decision Analysis Model of Survival Outcomes. Journal of Clinical Oncology, 2005, 23, 1911-1920.	0.8	33
170	Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scandinavian Journal of Urology and Nephrology, 2005, 39, 20-33.	1.4	114
171	Erectile Dysfunction Following Radical Prostatectomy. JAMA - Journal of the American Medical Association, 2005, 293, 2648.	3.8	79
172	Seminal Monolateral Nerve-Sparing Radical Prostatectomy in Selected Patients. Urologia Internationalis, 2005, 75, 175-180.	0.6	15
173	Radical Prostatectomy for Localized Prostate Cancer in a Liver Transplant Recipient. Urologia Internationalis, 2005, 74, 95-96.	0.6	4
174	Evaluation and Management of Prostate-specific Antigen Recurrence After Radical Prostatectomy for Localized Prostate Cancer. Japanese Journal of Clinical Oncology, 2005, 35, 365-374.	0.6	26

#	Article	IF	Citations
175	The role of lymphadenectomy in prostate cancer. Nature Reviews Urology, 2005, 2, 336-342.	1.4	30
176	COMPARISON OF PREDICTIVE ACCURACY FOR PATHOLOGICALLY ORGAN CONFINED CLINICAL STAGE T1c PROSTATE CANCER USING HUMAN GLANDULAR KALLIKREIN 2 AND PROSTATE SPECIFIC ANTIGEN COMBINED WITH CLINICAL STAGE AND GLEASON GRADE. Journal of Urology, 2005, 173, 752-756.	0.2	25
177	External Beam Radiotherapy as Curative Treatment of Prostate Cancer. Mayo Clinic Proceedings, 2005, 80, 883-898.	1.4	11
178	Surgical Management of Prostate Cancer: Optimizing Patient Selections and Clinical Outcome. Surgical Oncology Clinics of North America, 2005, 14, 301-319.	0.6	1
179	INDIVIDUALIZATION OF THE BIOPSY PROTOCOL ACCORDING TO THE PROSTATE GLAND VOLUME FOR PROSTATE CANCER DETECTION. Journal of Urology, 2005, 173, 1536-1540.	0.2	57
180	CÃ¡ncer de prÃ³stata. DiagnÃ³stico y valoraciÃ³n de extensiÃ³n. EMC - UrologÃa, 2005, 37, 1-13.	0.0	0
181	PREDICTION OF EXTRAPROSTATIC EXTENSION IN THE NEUROVASCULAR BUNDLE BASED ON PROSTATE NEEDLE BIOPSY PATHOLOGY, SERUM PROSTATE SPECIFIC ANTIGEN AND DIGITAL RECTAL EXAMINATION. Journal of Urology, 2005, 173, 450-453.	0.2	80
182	A NOVEL COMPUTER BASED EXPERT DECISION MAKING MODEL FOR PROSTATE CANCER DISEASE MANAGEMENT. Journal of Urology, 2005, 174, 2310-2318.	0.2	23
183	TRANSITION ZONE CANCERS UNDERMINE THE PREDICTIVE ACCURACY OF PARTIN TABLE STAGE PREDICTIONS. Journal of Urology, 2005, 173, 737-741.	0.2	45
184	THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CANCER OF THE PROSTATE RISK ASSESSMENT SCORE: A STRAIGHTFORWARD AND RELIABLE PREOPERATIVE PREDICTOR OF DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2005, 173, 1938-1942.	0.2	592
185	The bootstrap: A technique for data-driven statistics. Using computer-intensive analyses to explore experimental data. Clinica Chimica Acta, 2005, 359, 1-26.	0.5	230
186	Surgical management of prostate cancer: Advances based on a rational approach to the data. European Journal of Cancer, 2005, 41, 888-907.	1.3	29
187	Patients at high risk of progression after radical prostatectomy: Do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). European Journal of Cancer, 2005, 41, 2662-2672.	1.3	70
188	Preoperative Nomograms and Artificial Neural Networks (ANNs) for Identification of Surgical Candidates. EAU Update Series, 2005, 3, 63-71.	0.5	2
189	Additional use of [â˜2] precursor prostate-specific antigen and â€œbenignâ€•PSA at diagnosis in screen-detected prostate cancer. Urology, 2005, 65, 926-930.	0.5	23
191	The Natural History of Clinically Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2005, 293, 2149.	3.8	7
192	Management Strategies for Locally Advanced Prostate Cancer. Drugs and Aging, 2006, 23, 119-129.	1.3	10
193	Preoperative Nomograms for Predicting Stone-Free Rate After Extracorporeal Shock Wave Lithotripsy. Journal of Urology, 2006, 176, 1453-1457.	0.2	125

#	Article	IF	Citations
195	Laparoscopic Radical Prostatectomy: Impact of Modified Apical and Posterolateral Dissection In Reduction of Positive Surgical Margins in Patients with Clinical Stage T2 Prostate Cancer and High Risk of Extracapsular Extension. Journal of Endourology, 2006, 20, 332-339.	1.1	9
196	Karolinska prostatectomy: A robot-assisted laparoscopic radical prostatectomy technique. Scandinavian Journal of Urology and Nephrology, 2006, 40, 453-458.	1.4	32
197	The role of radiotherapy in the treatment of locally advanced prostate cancer. Community Oncology, 2006, 3, 759-764.	0.2	0
198	The role of whole pelvic radiotherapy in locally advanced prostate cancer. Radiotherapy and Oncology, 2006, 79, 1-14.	0.3	32
199	Guidelines for primary radiotherapy of patients with prostate cancer. Radiotherapy and Oncology, 2006, 79, 259-269.	0.3	139
200	Laparoscopic Radical Prostatectomy: Lessons Learned in Surgical Technique. European Urology Supplements, 2006, 5, 942-949.	0.1	4
201	Vaciamiento ganglionar en el cÃ¡ncer de prÃ³stata. EMC - UrologÃa, 2006, 38, 1-5.	0.0	0
205	Preoperative Parameters, Including Percent Positive Biopsy, in Predicting Seminal Vesicle Involvement in Patients with Prostate Cancer. Journal of Urology, 2006, 175, 518-522.	0.2	19
206	Is Biopsy Gleason Score Independently Associated With Biochemical Progression Following Radical Prostatectomy After Adjusting for Pathological Gleason Score?. Journal of Urology, 2006, 176, 2453-2458.	0.2	28
207	Update on Radiation Therapy in Prostate Cancer. Hematology/Oncology Clinics of North America, 2006, 20, 857-878.	0.9	5
208	Prostate Cancer Imaging. Seminars in Roentgenology, 2006, 41, 139-149.	0.2	6
209	Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology, 2006, 67, 115-119.	0.5	34
210	Laparoscopic extended pelvic lymph node dissection for high-risk prostate cancer. Urology, 2006, 68, 883-887.	0.5	39
211	External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology, 2006, 68, 1152-1155.	0.5	104
212	Expectant treatment with curative intent in the prostate-specific antigen era: Triggers for definitive therapy. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 51-57.	0.8	21
213	A new nomogram to predict pathologic outcome following radical prostatectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2006, 32, 155-164.	0.7	7
214	Molecular biological analysis of the heterogeneous prostate cancer group Gleason score 7. Prostate, 2006, 66, 966-970.	1.2	8
215	The use of nomograms in the detection of prostate cancer. Prostate, 2006, 66, 1266-1267.	1.2	8

#	Article	IF	Citations
216	Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of <=10 ng/mL and biopsy Gleason score of <=6, and their influence on PSA progression-free survival after radical prostatectomy. BJU International, 2006, 97, 1173-1178.	1.3	69
217	Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. BJU International, 2006, 98, 549-553.	1.3	18
218	Comparison of Gleason grade and score between preoperative biopsy and prostatectomy specimens in prostate cancer. International Journal of Urology, 2006, 13, 555-559.	0.5	24
219	Radical retropubic prostatectomy: How I do it. Surgical Practice, 2006, 10, 111-113.	0.1	0
220	Total and free prostate-specific antigen indexes in prostate cancer screening: value and limitation for Japanese populations. Asian Journal of Andrology, 2006, 8, 429-434.	0.8	16
221	Interstitial Low Dose Rate Brachytherapy for Prostate Cancer â€" A Focus on Intermediate- and High-risk Disease. Clinical Oncology, 2006, 18, 513-518.	0.6	16
222	Case-Matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1092-1099.	0.4	43
223	Use of nomograms as predictive tools in bladder cancer. World Journal of Urology, 2006, 24, 489-498.	1.2	13
224	Three-dimensional combination of transrectal and transperineal biopsies for efficient detection of stage T1c prostate cancer. International Journal of Clinical Oncology, 2006, 11, 127-132.	1.0	40
225	Long-term functional and oncological results after retroperitoneal laparoscopic prostatectomy according to a prospective evaluation of 550 patients. World Journal of Urology, 2006, 24, 281-288.	1.2	62
226	Metastatic lymph nodes in urogenital cancers: contribution of imaging findings. Abdominal Imaging, 2006, 31, 620-629.	2.0	25
227	Cross-sectional imaging of nodal metastases in the abdomen and pelvis. Abdominal Imaging, 2006, 31, 632-643.	2.0	77
228	Transperineal Permanent Seed Implantation of â€œLow-Riskâ€•Prostate Cancer. Strahlentherapie Und Onkologie, 2006, 182, 666-671.	1.0	16
231	Management and Survival of Screen-Detected Prostate Cancer Patients who Might Have Been Suitable for Active Surveillance. European Urology, 2006, 50, 475-482.	0.9	67
232	Outcomes Research: A Methodologic Review. European Urology, 2006, 50, 218-224.	0.9	19
233	Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy. Cancer, 2006, 106, 2369-2375.	2.0	47
234	Current status of lymph node-positive prostate cancer. Cancer, 2006, 107, 439-450.	2.0	58
235	Clinically localised prostate cancer. BMJ: British Medical Journal, 2006, 333, 1102-1106.	2.4	20

#	Article	IF	Citations
236	Prediction of Organ-confined Prostate Cancer: Incremental Value of MR Imaging and MR Spectroscopic Imaging to Staging Nomograms. Radiology, 2006, 238, 597-603.	3.6	237
237	Combined Endorectal and Phased-Array MRI in the Prediction of Pelvic Lymph Node Metastasis in Prostate Cancer. American Journal of Roentgenology, 2006, 186, 743-748.	1.0	83
238	External-Beam Radiotherapy for Localized Prostate Cancer. New England Journal of Medicine, 2006, 355, 1583-1591.	13.9	44
239	Allelic imbalance and biochemical outcome after radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2006, 9, 160-168.	2.0	3
240	PSA testing: an evolving relationship with prostate cancer screening. Prostate Cancer and Prostatic Diseases, 2006, 9, 6-13.	2.0	51
241	Progress in SPECT/CT Imaging of Prostate Cancer. Technology in Cancer Research and Treatment, 2006, 5, 329-336.	0.8	20
242	Predictive Ability of Partin Tables 2001 in a Welsh Population. Urologia Internationalis, 2006, 76, 217-222.	0.6	6
243	How Far Is the Preoperative Kattan Nomogram Applicable for the Prediction of Recurrence after Prostatectomy in Patients Presenting with PSA Levels of More than 20 ng/ml?. Urologia Internationalis, 2006, 77, 222-226.	0.6	7
244	Evolving treatment paradigms for locally advanced and metastatic prostate cancer. Expert Review of Anticancer Therapy, 2006, 6, 1639-1651.	1.1	3
246	Surgery Insight: optimizing open nerve-sparing radical prostatectomy techniques for improved outcomes. Nature Reviews Urology, 2007, 4, 561-569.	1.4	9
247	Should physicians use the updated Partin tables to predict pathologic stage in patients with prostate cancer?. Nature Reviews Urology, 2007, 4, 592-593.	1.4	1
248	Imaging Prostate Cancer: A Multidisciplinary Perspective. Radiology, 2007, 243, 28-53.	3.6	542
249	Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2007, 18, ii36-ii37.	0.6	6
250	Prediction of Seminal Vesicle Invasion in Prostate Cancer: Incremental Value of Adding Endorectal MR Imaging to the Kattan Nomogram. Radiology, 2007, 242, 182-188.	3.6	143
251	External Validation of a Nomogram for Prediction of Side-Specific Extracapsular Extension at Robotic Radical Prostatectomy. Journal of Endourology, 2007, 21, 1345-1352.	1.1	21
252	Collagen XXIII Expression Is Associated with Prostate Cancer Recurrence and Distant Metastases. Clinical Cancer Research, 2007, 13, 2634-2642.	3.2	39
253	Improved Accuracy for Predicting the Gleason Score of Prostate Cancer by Increasing the Number of Transrectal Biopsy Cores. Urologia Internationalis, 2007, 79, 302-306.	0.6	25
254	PSA Failure Following Definitive Treatment of Prostate Cancer Having Biopsy Gleason Score 7 With Tertiary Grade 5. JAMA - Journal of the American Medical Association, 2007, 298, 1533-8.	3.8	61

#	Article	IF	Citations
255	Prostate and Lymph Node Proton Magnetic Resonance (MR) Spectroscopic Imaging with External Array Coils at 3 T to Detect Recurrent Prostate Cancer After Radiation Therapy. Investigative Radiology, 2007, 42, 420-427.	3.5	25
256	Incremental Value of Multiplanar Cross-Referencing for Prostate Cancer Staging with Endorectal MRI. American Journal of Roentgenology, 2007, 188, 99-104.	1.0	30
257	Predicting outcomes in patients with urologic cancers. Current Opinion in Supportive and Palliative Care, 2007, 1, 153-168.	0.5	4
258	Dosimetry of an Extracapsular Anulus Following Permanent Prostate Brachytherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 228-233.	0.6	19
259	Postoperative Inguinal Hernia After Radical Prostatectomy for Prostate Cancer. Urology, 2007, 69, 326-329.	0.5	80
260	Role of Pelvic Lymphadenectomy in Prostate Cancer Management. Urology, 2007, 69, 203-209.	0.5	30
261	Prostate-Specific Antigen Density Predicts Adverse Pathology and Increased Risk of Biochemical Failure. Urology, 2007, 69, 1121-1127.	0.5	54
262	Updated Nomogram to Predict Pathologic Stage of Prostate Cancer Given Prostate-Specific Antigen Level, Clinical Stage, and Biopsy Gleason Score (Partin Tables) Based on Cases from 2000 to 2005. Urology, 2007, 69, 1095-1101.	0.5	410
263	Risk Stratification of Men with Gleason Score 7 to 10 Tumors by Primary and Secondary Gleason Score: Results from the SEARCH Database. Urology, 2007, 70, 277-282.	0.5	46
264	Changes in Prognostic Significance and Predictive Accuracy of Gleason Grading System Throughout PSA Era: Impact of Grade Migration in Prostate Cancer. Urology, 2007, 70, 706-710.	0.5	17
265	Survival benefit for early hormone ablation in biochemically recurrent prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 101-109.	0.8	23
266	Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics, 2007, 89, 666-672.	1.3	93
267	The Evolution of Staging of Lymph Node Metastases in Clinically Localized Prostate Cancer. EAU-EBU Update Series, 2007, 5, 153-162.	0.7	5
268	Transrectal high-intensity focused ultrasound ablation of prostate cancer: Effective treatment requiring accurate imaging. European Journal of Radiology, 2007, 63, 317-327.	1.2	71
269	Localised and Locally Advanced Prostate Cancer: Who to Treat and How?. European Urology Supplements, 2007, 6, 334-343.	0.1	4
270	Prostate Cancer: Highlights from 2006. European Urology Supplements, 2007, 6, 728-736.	0.1	2
271	Advances in Oncological Urologyâ€"the Oncoforum Programme. European Urology Supplements, 2007, 6, 821-828.	0.1	3
272	Evidence-based radiation oncology: Definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiotherapy and Oncology, 2007, 84, 197-215.	0.3	70

#	Article	IF	Citations
273	Complete Resection of Seminal Vesicles at Radical Prostatectomy Results in Substantial Long-Term Disease-Free Survival: Multi-institutional Study of 6740 Patients. Urology, 2007, 69, 536-540.	0.5	36
274	Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncology, The, 2007, 8, 411-419.	5.1	50
275	Surgery alone for advanced prostate cancer?. European Journal of Cancer, Supplement, 2007, 5, 157-169.	2.2	1
276	Adjuvant radiotherapy after radical prostatectomy. European Journal of Cancer, Supplement, 2007, 5, 171-176.	2.2	4
277	Adjuvant Radiotherapy after Radical Prostatectomy: Indications, Results and Side Effects. Urologia Internationalis, 2007, 78, 193-197.	0.6	24
278	Prostate cancer: To scan or not to scan for lymph node involvement?. Scandinavian Journal of Urology and Nephrology, 2007, 41, 501-506.	1.4	2
280	Sentinel Lymph Node Dissection for Prostate Cancer: Experience With More Than 1,000 Patients. Journal of Urology, 2007, 177, 916-920.	0.2	152
282	Clinico-pathological Characteristics of Prostate Cancer in Korean Men and Nomograms for the Prediction of the Pathological Stage of the Clinically Localized Prostate Cancer: A Multi-institutional Update. Korean Journal of Urology, 2007, 48, 125.	0.2	12
283	Development of Nomogram for Predicting Pathologic Outcome using Prostate-specific Antigen, Gleason Score, and the Percentage of Positive Core in the Clinically Confined Prostate Cancers, and Comparison with Nomogram using Existing Factors. Korean Journal of Urology, 2007, 48, 789.	0.2	1
284	The Role of Pelvic Lymphadenectomy in the Management of Prostate and Bladder Cancer. Scientific World Journal, The, 2007, 7, 789-799.	0.8	12
285	Imaging in genitourinary cancer from the urologistsï¿½	1.2	14
286	Diagnostic Performance of a Random Versus Lesion-Directed Biopsy of the Prostate From Transrectal Ultrasound. Journal of Ultrasound in Medicine, 2007, 26, 11-17.	0.8	15
287	Nuclear and Cytoplasmic Expression of ErbB-4 in Prostate Cancer. International Journal of Biological Markers, 2007, 22, 181-185.	0.7	2
288	The prognostic significance of perineural invasion in prostatic cancer biopsies. Cancer, 2007, 109, 13-24.	2.0	158
289	Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer. Cancer, 2007, 110, 289-296.	2.0	32
290	When Should the Seminal Vesicles be Included in the Target Volume in Prostate Radiotherapy?. Clinical Oncology, 2007, 19, 302-307.	0.6	25
291	Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel nodeâ€"based, intensity-modulated radiation therapy technique. International Journal of Radiation Oncology Biology Physics, 2007, 67, 347-355.	0.4	47
292	Androgen Deprivation Therapy Does Not Impact Cause-Specific or Overall Survival in High-Risk Prostate Cancer Managed With Brachytherapy and Supplemental External Beam. International Journal of Radiation Oncology Biology Physics, 2007, 68, 34-40.	0.4	48

#	Article	IF	Citations
293	Radiotherapy After Prostatectomy: Improved Biochemical Relapse-Free Survival With Whole Pelvic Compared With Prostate Bed Only for High-Risk Patients. International Journal of Radiation Oncology Biology Physics, 2007, 69, 54-61.	0.4	136
294	Prediction of Radial Distance of Extraprostatic Extension FromÂPretherapy Factors. International Journal of Radiation Oncology Biology Physics, 2007, 69, 411-418.	0.4	18
296	11C-Choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU International, 2007, 99, 1421-1426.	1.3	57
297	Reliability of preoperative diagnostics and location of lymph node metastases in presumed unilateral prostate cancer. BJU International, 2007, 99, 1036-1040.	1.3	34
298	Molecular markers and mortality in prostate cancer. BJU International, 2007, 100, 1259-1263.	1.3	31
299	Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU International, 2007, 100, 1240-1244.	1.3	39
300	ENDORECTAL MAGNETIC RESONANCE IMAGING STAGING OF PROSTATE CANCER. ANZ Journal of Surgery, 2007, 77, 860-865.	0.3	26
301	Low Gleason score prostatic adenocarcinomas are no longer viable entities. Histopathology, 2007, 50, 683-690.	1.6	29
302	A Pretreatment Table for the Prediction of Final Histopathology after Radical Prostatectomy in Clinical Unilateral T3a Prostate Cancer. European Urology, 2007, 51, 388-396.	0.9	54
303	Prostatic Fascial Anatomy and Positive Surgical Margins in Laparoscopic Radical Prostatectomy. European Urology, 2007, 51, 598-600.	0.9	19
304	Prediction of Pathological Stage is Inaccurate in Men with PSA Values above 20ng/mL. European Urology, 2007, 52, 1374-1380.	0.9	16
305	Detection Rate and Operating Time Required for Î³ Probe-Guided Sentinel Lymph Node Resection after Injection of Technetium-99m Nanocolloid into the Prostate with and without Preoperative Imaging. European Urology, 2007, 52, 126-133.	0.9	73
306	Prospective Validation of Active Surveillance in Prostate Cancer: The PRIAS Study. European Urology, 2007, 52, 1560-1563.	0.9	212
307	Towards a practical Fourier transform infrared chemical imaging protocol for cancer histopathology. Analytical and Bioanalytical Chemistry, 2007, 389, 1155-1169.	1.9	177
308	Role of nomograms for prostate cancer in 2007. World Journal of Urology, 2007, 25, 131-142.	1.2	48
309	Role of lymphadenectomy in clinically organ-confined prostate cancer. World Journal of Urology, 2007, 25, 39-44.	1.2	13
310	Optimal treatment of locally advanced prostate cancer. World Journal of Urology, 2007, 25, 169-176.	1.2	20
311	Prostate Risk Index (PRIX) as a New Method of Risk Classification for Clinically Localized Prostate Cancer. Strahlentherapie Und Onkologie, 2007, 183, 490-496.	1.0	14

#	Article	IF	Citations
312	Current status of intensity-modulated radiation therapy (IMRT). International Journal of Clinical Oncology, 2007, 12, 408-415.	1.0	24
313	Optimal cost-effective staging evaluations in prostate cancer. Current Urology Reports, 2007, 8, 190-196.	1.0	6
314	Current perspectives in the treatment of advanced prostate cancer. Medical Oncology, 2007, 24, 273-286.	1.2	13
315	Clinical impact of second pathology opinion: A longitudinal study of central genitourinary pathology review before prostate brachytherapy. Brachytherapy, 2007, 6, 135-141.	0.2	13
316	New implant technique for separation of the seminal vesicle and rectal mucosa for high-dose-rate prostate brachytherapy. Brachytherapy, 2007, 6, 180-186.	0.2	8
317	Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy. World Journal of Urology, 2008, 26, 447-456.	1.2	6
318	Watchful waiting versus active surveillance: Appropriate patient selection. Current Urology Reports, 2008, 9, 211-216.	1.0	10
319	The use of prostate-specific antigen kinetics to stratify risk in prostate cancer. Current Urology Reports, 2008, 9, 226-230.	1.0	4
320	Robot-assisted laparoscopic radical prostatectomy: an athermal anterior approach to the seminal vesicle dissection. Journal of Robotic Surgery, 2008, 2, 223-226.	1.0	4
322	Current trends in diagnostic and therapeutic principles for prostate cancer in Japan. International Journal of Clinical Oncology, 2008, 13, 239-243.	1.0	3
323	The role of endorectal coil MRI in preoperative staging and decision-making for the treatment of clinically localized prostate cancer. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2008, 21, 371-377.	1.1	26
324	An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2008, 21, 411-421.	1.1	27
325	MR imaging of the prostate in clinical practice. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2008, 21, 379-392.	1.1	64
326	Interobserver reproducibility of Gleason grading: evaluation using prostate cancer tissue microarrays. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1071-1078.	1.2	50
327	Surgery vs. radiotherapy in localized prostate cancer. Which is best?. Radiation Oncology, 2008, 3, 23.	1.2	20
328	CT, MRI and ultrasound scanning rates: Evaluation of cancer diagnosis, staging and surveillance in ontario. Journal of Surgical Oncology, 2008, 98, 490-499.	0.8	15
329	Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer, 2008, 112, 69-74.	2.0	65
330	The clinical management of patients with a small volume of prostatic cancer on biopsy: What are the risks of progression?. Cancer, 2008, 112, 971-981.	2.0	90

#	Article	IF	Citations
331	Active surveillance for earlyâ€stage prostate cancer. Cancer, 2008, 112, 1650-1659.	2.0	252
332	Should patients consider active surveillance?. Cancer, 2008, 112, 2631-2634.	2.0	3
333	An updated catalog of prostate cancer predictive tools. Cancer, 2008, 113, 3075-3099.	2.0	238
334	Primary Causes of Death After Permanent Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2008, 72, 433-440.	0.4	57
335	Brachytherapy Doses for Prostate Cancer Customized to Risk Factors: Is It More Important â€œHow Muchâ€•or â€œWhereâ€? In Regard to Stone et al. (Int J Radiat Oncol Biol Phys 2007;69:1472â€“1477). International Journal of Radiation Oncology Biology Physics, 2008, 71, 962.	0.4	1
336	In Reply to Dr. Cheng. International Journal of Radiation Oncology Biology Physics, 2008, 71, 961-962.	0.4	0
337	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clinical Chemistry, 2008, 54, e11-e79.	1.5	539
338	Radical Prostatectomy. Annals of the New York Academy of Sciences, 2008, 1138, 267-277.	1.8	13
339	Molecular and prognostic markers in prostate cancer. Apmis, 2008, 116, 1-62.	0.9	0
340	Value of power Doppler sonography with 3D reconstruction in preoperative diagnostics of extraprostatic tumor extension in clinically localized prostate cancer. International Journal of Urology, 2008, 15, 68-75.	0.5	19
341	Evidenceâ€based Clinical Practice Guidelines for Prostate Cancer (Summary â€“ JUA 2006 Edition). International Journal of Urology, 2008, 15, 1-18.	0.5	17
342	Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. International Journal of Urology, 2008, 15, 520-523.	0.5	14
343	New bloodâ€based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU International, 2008, 101, 675-683.	1.3	55
344	Is robotically assisted laparoscopic radical prostatectomy less invasive than retropubic radical prostatectomy? Results from a prospective, unrandomized, comparative study. BJU International, 2008, 101, 1145-1149.	1.3	70
345	An Analysis of Radical Prostatectomy in Advanced Stage and High-Grade Prostate Cancer. European Urology, 2008, 53, 253-259.	0.9	101
346	Adjuvant Radiotherapy for Patients with Locally Advanced Prostate Cancerâ€”A New Standard?. European Urology, 2008, 54, 528-542.	0.9	42
347	Combined Permanent Implant and External-Beam Radiation Therapy for Prostate Cancer. Seminars in Radiation Oncology, 2008, 18, 23-34.	1.0	6
348	Pelvic Lymph Node Irradiation for Prostate Cancer: Who, Why, and When?. Seminars in Radiation Oncology, 2008, 18, 35-40.	1.0	16

#	Article	IF	Citations
349	Prostate Cancer Staging Tablesâ€"A Predictive Model for the UK. British Journal of Medical and Surgical Urology, 2008, 1, 107-119.	0.2	1
350	Significance of Tertiary Gleason Pattern 5 in Gleason Score 7 Radical Prostatectomy Specimens. Journal of Urology, 2008, 179, 516-522.	0.2	69
352	The Effect of Race/Ethnicity on the Accuracy of the 2001 Partin Tables for Predicting Pathologic Stage of Localized Prostate Cancer. Urology, 2008, 71, 151-155.	0.5	14
353	Impact of Common Iliac Nodal Treatment on Radiation Outcomes in Localized Prostate Cancer. Urology, 2008, 71, 313-317.	0.5	2
354	Assessment of Biochemical Recurrence Rate in Patients With Pathologically Confirmed Insignificant Prostate Cancer. Urology, 2008, 72, 1208-1211.	0.5	13
355	The Newer the Better? Comparison of the 1997 and 2001 Partin Tables for Pathologic Stage Prediction of Prostate Cancer in China. Urology, 2008, 72, 1096-1101.	0.5	7
356	Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 158-165.	0.8	33
357	Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 408-414.	0.8	9
358	The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clinical Radiology, 2008, 63, 387-395.	0.5	800
359	Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clinical Radiology, 2008, 63, 774-782.	0.5	234
360	Estrategias terapÃ©uticas del cÃ¡ncer de prÃ³stata de estadio T3. EMC - UrologÃa, 2008, 40, 1-11.	0.0	0
361	What is the Role of Surgery for Locally Advanced Disease?. European Urology Supplements, 2008, 7, 400-405.	0.1	6
362	Prostate cancer. Lancet, The, 2008, 371, 1710-1721.	6.3	421
363	Best Practice Statement on Cryosurgery for the Treatment of Localized Prostate Cancer. Journal of Urology, 2008, 180, 1993-2004.	0.2	219
364	External Validation of the Updated Partin Tables in a Cohort of North American Men. Journal of Urology, 2008, 180, 898-903.	0.2	36
365	Validation of Partin Tables and Development of a Preoperative Nomogram for Japanese Patients With Clinically Localized Prostate Cancer Using 2005 International Society of Urological Pathology Consensus on Gleason Grading: Data From the Clinicopathological Research Group for Localized Prostate Cancer. Journal of Urology, 2008, 180, 904-910.	0.2	70
367	Pretreatment Predictors of Death From Other Causes in Men With Prostate Cancer. Journal of Urology, 2008, 180, 2447-2452.	0.2	18
370	The postchemotherapy PSA surge syndrome. Annals of Oncology, 2008, 19, 1308-1311.	0.6	60

#	Article	IF	Citations
371	Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2008, 19, ii45-ii46.	0.6	14
372	Radical Prostatectomy in the 21st Century â€“ The Gold Standard for Localized and Locally Advanced Prostate Cancer. , 2008, 41, 7-14.		13
373	Lymphadenectomy in Prostate Cancer. , 2008, 41, 58-67.		8
374	Postoperative Adjuvant Radiotherapy â€“ Standard of Care?. , 2008, 41, 32-38.		1
375	Urological Oncology. , 2008, , .		3
376	Pelvic lymphadenectomy in prostate cancer. Prostate Cancer and Prostatic Diseases, 2008, 11, 320-324.	2.0	17
377	Hormone Therapy for Prostate Cancer â€“ Immediate Initiation. , 2008, 41, 49-57.		2
378	New circulating biomarkers for prostate cancer. Prostate Cancer and Prostatic Diseases, 2008, 11, 112-120.	2.0	65
379	Genomic Alterations Indicate Tumor Origin and Varied Metastatic Potential of Disseminated Cells from Prostate Cancer Patients. Cancer Research, 2008, 68, 5599-5608.	0.4	50
380	Predictive models and prostate cancer. Nature Reviews Urology, 2008, 5, 82-92.	1.4	28
381	Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression. Nature Reviews Urology, 2008, 5, 277-283.	1.4	17
382	Risk Stratification for Positive Lymph Nodes in Prostate Cancer. Journal of Endourology, 2008, 22, 1021-1026.	1.1	4
383	Generalized Caseview applied to prostate cancer prognosis. , 2008, 2008, 5129-31.		0
384	Planned Nerve Preservation to Reduce Positive Surgical Margins during Robot-Assisted Laparoscopic Radical Prostatectomy. Journal of Endourology, 2008, 22, 1303-1310.	1.1	42
385	What Is Adequate Management to Preserve Erectile Function after Unilateral Nerve-Sparing Radical Prostatectomy?. Journal of Endourology, 2008, 22, 2029-2032.	1.1	4
389	Imaging recurrent prostate cancer. , 0, , 195-222.		1
393	Definitive Radiotherapy for Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 496-503.	0.6	24
394	Inventory of prostate cancer predictive tools. Current Opinion in Urology, 2008, 18, 279-296.	0.9	73

#	Article	IF	Citations
395	Biochemical and Functional Outcomes Following Brachytherapy With or Without Supplemental Therapies in Men â‰¥50 Years of Age With Clinically Organ-Confined Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 539-544.	0.6	11
396	The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: The Beth Israel Deaconess Medical Center (BIDMC) approach. Cancer Biomarkers, 2008, 4, 251-262.	0.8	27
397	Gleason score as predictor of clinicopathologic findings and biochemical (PSA) progression following radical prostatectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2008, 34, 23-29.	0.7	14
398	The incidence of lymph node metastases in prostate carcinoma depends not only on tumor characteristics but also on surgical performance and extent of pelvic lymphadenectomy. Medicina (Lithuania), 2008, 44, 601.	0.8	5
400	Incremental value of magnetic resonance imaging in the advanced management of prostate cancer. World Journal of Radiology, 2009, 1, 3.	0.5	8
401	Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2009, 20, iv76-iv78.	0.6	28
402	Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the partin tables. Acta Radiologica, 2009, 50, 562-569.	0.5	83
403	Correlation between Upgrading of Prostate Biopsy and Biochemical Failure and Unfavorable Pathology after Radical Prostatectomy. Urologia Internationalis, 2009, 83, 146-150.	0.6	7
404	Natural Orifice Translumenal Endoscopic Surgical Radical Prostatectomy: Proof of Concept. Journal of Endourology, 2009, 23, 669-675.	1.1	41
406	Prostatakarzinom. , 2009, , 485-635.		0
407	Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers. Journal of Clinical Oncology, 2009, 27, 4986-4993.	0.8	57
408	Three-Dimensional Prostate Mapping Biopsy Has a Potentially Significant Impact on Prostate Cancer Management. Journal of Clinical Oncology, 2009, 27, 4321-4326.	0.8	193
409	MEK4 Function, Genistein Treatment, and Invasion of Human Prostate Cancer Cells. Journal of the National Cancer Institute, 2009, 101, 1141-1155.	3.0	96
410	Prostate Cancer: Sextant Localization at MR Imaging and MR Spectroscopic Imaging before Prostatectomyâ€"Results of ACRIN Prospective Multi-institutional Clinicopathologic Study. Radiology, 2009, 251, 122-133.	3.6	223
411	Helical Tomotherapy with Simultaneous Integrated Boost for High-Risk and Lymph Node-Positive Prostate Cancer: Early Report on Acute and Late Toxicity. Technology in Cancer Research and Treatment, 2009, 8, 353-359.	0.8	32
412	Adjuvant therapy after radical prostatectomy: Clinical considerations. Surgical Oncology, 2009, 18, 247-254.	0.8	4
413	The clinical significance and therapeutic implications of extraprostatic invasion. Surgical Oncology, 2009, 18, 203-212.	0.8	3
414	Risk-Adjusted Hazard Rates of Biochemical Recurrence for Prostate Cancer Patients after Radical Prostatectomy. European Urology, 2009, 55, 412-421.	0.9	18

#	Article	IF	Citations
415	Patient selection for hemiablative focal therapy of prostate cancer. Cancer, 2009, 115, 2104-2110.	2.0	57
416	Lymph node assessment and lymphadenectomy in prostate cancer. Journal of Surgical Oncology, 2009, 99, 215-224.	0.8	10
418	Comparison of Biochemical Relapse-Free Survival Between Primary Gleason Score 3 and Primary Gleason Score 4 for Biopsy Gleason Score 7 Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1439-1445.	0.4	57
419	Watchful waiting versus active surveillance: Appropriate patient selection. Current Prostate Reports, 2009, 7, 5-10.	0.1	0
420	The use of prostate-specific antigen kinetics to stratify risk in prostate cancer. Current Prostate Reports, 2009, 7, 11-15.	0.1	0
421	cExternal beam radiation results in minimal changes in post void residual urine volumes during the treatment of clinically localized prostate cancer. Radiation Oncology, 2009, 4, 26.	1.2	1
422	Prostate cancer: diagnosis and staging. Asian Journal of Andrology, 2009, 11, 74-80.	0.8	55
423	Trends in radical prostatectomy. International Journal of Urology, 2009, 16, 151-160.	0.5	10
424	The relationship between preoperative prostateâ€specific antigen and biopsy Gleason sum in men undergoing radical retropubic prostatectomy: a novel assessment of traditional predictors of outcome. BJU International, 2009, 103, 38-42.	1.3	8
425	How often do available preoperative risk factors accurately predict the risk assessed after surgery for localized prostate cancer?. BJU International, 2009, 103, 317-320.	1.3	0
426	Can nomograms be superior to other prediction tools?. BJU International, 2009, 103, 492-497.	1.3	108
427	Fiveâ€year longitudinal effect of radical perineal prostatectomy on healthâ€related quality of life in Japanese men, using general and diseaseâ€specific measures. BJU International, 2009, 104, 1077-1084.	1.3	14
428	Pretreatment Endorectal Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging Features of Prostate Cancer as Predictors of Response to External Beam Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 73, 665-671.	0.4	52
429	External Validation of the Updated Partin Tables in a Cohort of French and Italian Men. International Journal of Radiation Oncology Biology Physics, 2009, 73, 347-352.	0.4	46
430	Pretreatment Serum Testosterone and Androgen Deprivation: Effect on Disease Recurrence and Overall Survival in Prostate Cancer Patients Treated With Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1143-1149.	0.4	15
431	Dosimetric Study of Pelvic Proton Radiotherapy for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 994-1002.	0.4	62
432	Prostate cancer control and survival in Vietnam veterans exposed to Agent Orange. Brachytherapy, 2009, 8, 57-62.	0.2	4
433	Treatment of early prostate cancer: radical prostatectomy. Trends in Urology Gynaecology & Sexual Health, 2009, 14, 10-15.	0.1	2

#	Article	IF	Citations
434	Radioisotope guided sentinel lymph node dissection in patients with localized prostate cancer: Results of the first 100 cases. European Journal of Surgical Oncology, 2009, 35, 751-756.	0.5	16
435	Partin Tables cannot accurately predict the pathological stage at radical prostatectomy. European Journal of Surgical Oncology, 2009, 35, 123-128.	0.5	28
437	Does Benign Prostatic Tissue Contribute to Measurable PSA Levels After Radical Prostatectomy?. Urology, 2009, 74, 167-170.	0.5	35
438	Significant Change in Predicted Risk of Biochemical Recurrence After Radical Prostatectomy More Common in Black Than in White Men. Urology, 2009, 74, 660-664.	0.5	4
439	Predictive Value of Prostate-specific Antigen Expression in Prostate Cancer: A Tissue Microarray Study. Urology, 2009, 74, 1169-1173.	0.5	18
440	Commentary on Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 457-458.	0.8	0
441	Multiple prostate cancer cores with different Gleason grades submitted in the same specimen container without specific site designation: should each core be assigned an individual Gleason score?. Human Pathology, 2009, 40, 558-564.	1.1	35
442	Inappropriate treatment of prostate cancer caused by heterophilic antibody interference. Nature Reviews Urology, 2009, 6, 164-167.	1.9	15
443	Critical review of prostate cancer predictive tools. Future Oncology, 2009, 5, 1555-1584.	1.1	162
444	Focal Targeted Therapy Will Be a Future Treatment Modality for Early Stage Prostate Cancer. European Urology Supplements, 2009, 8, 424-432.	0.1	13
446	PET Imaging of Prostate Cancer Using Radiolabeled Choline. PET Clinics, 2009, 4, 173-184.	1.5	12
447	Preoperative Prognostic Nomogram (Probability Table) for Renal Cell Carcinoma Based on TNM Classification. Journal of Urology, 2009, 181, 480-485.	0.2	27
448	Nomogram Predicting the Probability of Early Recurrence After Radical Prostatectomy for Prostate Cancer. Journal of Urology, 2009, 181, 601-608.	0.2	129
449	Radioterapia conformada en pacientes con cÃ¡ncer de prÃ³stata Experiencia de tres aÃ±os en el Instituto Nacional de CancerologÃa de Colombia. Revista Colombiana De CancerologÃa, 2009, 13, 124-133.	0.0	2
450	Predictors of Positive Surgical Margins After Laparoscopic Robot Assisted Radical Prostatectomy. Journal of Urology, 2009, 182, 2682-2688.	0.2	66
452	Intraoperative Photodynamic Evaluation of Surgical Margins During Endoscopic Extraperitoneal Radical Prostatectomy with the Use of 5-Aminolevulinic Acid. Journal of Endourology, 2009, 23, 1387-1394.	1.1	18
453	Nerve-sparing focal cryoablation of prostate cancer. Current Opinion in Urology, 2009, 19, 182-187.	0.9	23
456	Prostate Cancer With Tertiary Gleason Pattern 5 in Prostate Needle Biopsy. American Journal of Surgical Pathology, 2009, 33, 233-240.	2.1	39

#	Article	IF	Citations
458	PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1106-1116.	3.3	119
459	Whole-Pelvis Radiotherapy in Combination With Interstitial Brachytherapy: Does Coverage of the Pelvic Lymph Nodes Improve Treatment Outcome in High-Risk Prostate Cancer?. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1078-1084.	0.4	28
460	Novel predictive tools for Irish radical prostatectomy pathological outcomes: development and validation. Irish Journal of Medical Science, 2010, 179, 187-195.	0.8	2
461	Predictive and Prognostic Models in Radical Prostatectomy Candidates: A Critical Analysis of the Literature. European Urology, 2010, 58, 687-700.	0.9	132
462	A cell kinetics model for prostate cancer and its application to clinical data and individual patients. Journal of Theoretical Biology, 2010, 264, 420-442.	0.8	8
463	Guided e-MRI prostate biopsy can solve the discordance between Gleason score biopsy and radical prostatectomy pathology. Magnetic Resonance Imaging, 2010, 28, 943-946.	1.0	18
464	External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: The initial experience of the Catalan Institute of Oncology. Brachytherapy, 2010, 9, 15-22.	0.2	28
465	The impact of perineural invasion on biochemical outcome after permanent prostate iodine-125 brachytherapy. Brachytherapy, 2010, 9, 213-218.	0.2	6
466	Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Critical Reviews in Oncology/Hematology, 2010, 73, 68-91.	2.0	105
467	Permanent Prostate Brachytherapy in Prostate Glands <20 cm3. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1450-1455.	0.4	20
468	Greater Biopsy Core Number Is Associated With Improved Biochemical Control in Patients Treated With Permanent Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1104-1110.	0.4	6
469	Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Medical Genomics, 2010, 3, 8.	0.7	219
470	Predictive models before and after radical prostatectomy. Prostate, 2010, 70, 1371-1378.	1.2	27
471	Adequacy of lymphadenectomy among men undergoing robotâ€assisted laparoscopic radical prostatectomy. BJU International, 2010, 105, 88-92.	1.3	53
472	Relationship between prostate cancer mortality and number of unfavourable risk factors in men treated with definitive brachytherapy. BJU International, 2010, 106, 809-814.	1.3	5
473	Development and internal validation of a nomogram predicting extracapsular extension in radical prostatectomy specimens. International Journal of Urology, 2010, 17, 267-272.	0.5	27
474	Nomogram to predict seminal vesicle invasion using the status of cancer at the base of the prostate on systematic biopsy. International Journal of Urology, 2010, 17, 534-540.	0.5	9
475	Sobrevida e fatores prognÃ³sticos de pacientes com cÃ¢ncer de prÃ³stata clinicamente localizado. Revista De Saude Publica, 2010, 44, 344-352.	0.7	21

#	Article	IF	Citations
476	The Role of Endorectal Magnetic Resonance Imaging in Predicting Extraprostatic Extension and Seminal Vesicle Invasion in Clinically Localized Prostate Cancer. Korean Journal of Urology, 2010, 51, 308.	1.2	14
477	Association of Insurance and Race/Ethnicity with Disease Severity among Men Diagnosed with Prostate Cancer, National Cancer Database 2004-2006. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2437-2444.	1.1	54
478	Extraperitoneal Approach Induces Postoperative Inguinal Hernia Compared with Transperitoneal Approach after Laparoscopic Radical Prostatectomy. Japanese Journal of Clinical Oncology, 2010, 40, 349-352.	0.6	31
479	Will the Modification of the Gleason Grading System Affect the Urology Practice?. International Journal of Surgical Pathology, 2010, 18, 248-254.	0.4	23
480	External Validation of the 2007 and 2001 Partin Tables in Irish Prostate Cancer Patients. Urologia Internationalis, 2010, 84, 174-179.	0.6	11
481	The Role of Lymphadenectomy in Minimally Invasive Urologic Oncology. Journal of Endourology, 2010, 24, 1229-1240.	1.1	3
482	Outcome of Patients with Localized Prostate Cancer Treated by Radiotherapy After Confirming the Absence of Lymph Node Invasion. Japanese Journal of Clinical Oncology, 2010, 40, 652-657.	0.6	6
483	Validation of the Partin Nomogram for Prostate Cancer in a National Sample. Journal of Urology, 2010, 183, 105-111.	0.2	47
485	Prostate-specific Antigen Testing and Prostate Cancer Screening. Primary Care - Clinics in Office Practice, 2010, 37, 441-459.	0.7	11
486	Magnetic Resonance Imaging of Prostate Cancer. , 2010, , 125-141.		0
487	Handbook of Evidence-Based Radiation Oncology. , 2010, , .		45
488	Head to head comparison of three generations of Partin tables to predict final pathological stage in clinically localised prostate cancer. European Journal of Cancer, 2010, 46, 2235-2241.	1.3	9
489	Migration of intraprostatic fiducial markers and its influence on the matching quality in external beam radiation therapy for prostate cancer. Radiotherapy and Oncology, 2010, 96, 43-47.	0.3	39
490	Contemporary treatment of high-risk localized prostate cancer. Expert Review of Anticancer Therapy, 2010, 10, 1069-1076.	1.1	3
491	Contemporary Results of Focal Therapy for Prostate Cancer Using Cryoablation. Journal of Endourology, 2010, 24, 827-834.	1.1	21
492	Prostate Cancer: Multiparametric MR Imaging for Detection, Localization, and Staging. Radiology, 2011, 261, 46-66.	3.6	618
493	The correlation between annular treatment margins and biochemical failure in prostate brachytherapy patients with optimized intraprostatic dosimetry. Brachytherapy, 2011, 10, 409-415.	0.2	5
494	Prognostic role of perineural invasion in prostate biopsy. Actas UrolÃ³gicas EspaÃ±olas (English) Tj ETQq1 1 0.784314 rgBT /Overlock	0.2	1

#	Article	IF	Citations
495	Prostate. Medical Radiology, 2011, , 949-1025.	0.0	0
496	Role of Radiation Therapy for the Treatment of Lymph Nodes in Urologic Malignancies. Urologic Clinics of North America, 2011, 38, 497-506.	0.8	2
497	Choline PET/CT for prostate cancer: Main clinical applications. European Journal of Radiology, 2011, 80, e50-e56.	1.2	55
498	Synthesis and Preliminary Bioevaluation of ^{99m}Tc(CO)₃-17Î±-Triazolylandrost-4-Ene-3-One Derivative Prepared via Click Chemistry Route. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 539-545.	0.7	11
500	Place de la prostatectomie radicale dans le traitement du cancer de prostate. Medecine Nucleaire, 2011, 35, 384-389.	0.2	0
501	Effect of Whole Pelvic Radiotherapy for Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy and Long-Term Androgen Deprivation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e721-e726.	0.4	37
502	The Use of Models to Predict the Presence and Aggressiveness of Prostate Cancer on Prostate Biopsy. , 2011, , .		0
503	Role of Pelvic Lymph Node Dissection in Prostate Cancer Treatment. Korean Journal of Urology, 2011, 52, 437.	1.2	11
504	Tertiary Gleason pattern 5 on needle biopsy predicts greater tumour volume on radical prostatectomy. Pathology, 2011, 43, 693-696.	0.3	5
505	Endorectal magnetic resonance imaging has limited clinical ability to preoperatively predict pT3 prostate cancer. BJU International, 2011, 107, 1419-1424.	1.3	41
506	Prediction of patientâ€specific risk and percentile cohort risk of pathological stage outcome using continuous prostateâ€specific antigen measurement, clinical stage and biopsy Gleason score. BJU International, 2011, 107, 1562-1569.	1.3	36
508	PSA density versus risk stratification for lymphadenectomy-making decision in patients with prostate cancer undergoing radical prostatectomy. International Urology and Nephrology, 2011, 43, 1073-1079.	0.6	5
509	Combination of Dose Escalation with Technological Advances (Intensity-Modulated and Image-Guided) Tj ETQq0 0 0 rgBT /Overlock 10 T Strahlentherapie Und Onkologie, 2011, 187, 479-484.	1.0	46
511	Development of a real-time clinical decision support system upon the web mvc-based architecture for prostate cancer treatment. BMC Medical Informatics and Decision Making, 2011, 11, 16.	1.5	18
512	Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy. Cancer, 2011, 117, 3933-3942.	2.0	77
513	Long-Term Outcome for Clinically Localized Prostate Cancer Treated With Permanent Interstitial Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1336-1342.	0.4	144
514	In Response to Dr. Hayes and Colleagues. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1598-1599.	0.4	0
515	Pelvic Nodal Radiotherapy in Patients With Unfavorable Intermediate and High-Risk Prostate Cancer: Evidence, Rationale, and Future Directions. International Journal of Radiation Oncology Biology Physics, 2011, 80, 6-16.	0.4	76

#	Article	IF	Citations
516	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Modern Pathology, 2011, 24, 39-47.	2.9	127
517	Endorectal MRI of Prostate Cancer: Incremental Prognostic Importance of Gross Locally Advanced Disease. American Journal of Roentgenology, 2011, 197, 1369-1374.	1.0	16
518	ACR Appropriateness CriteriaÂ® Definitive External Beam Irradiation in Stage T1 and T2 Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 636-647.	0.6	3
519	Pathways of Lymphatic Spread in Male Urogenital Pelvic Malignancies. Radiographics, 2011, 31, 135-160.	1.4	104
520	Is Apparent Diffusion Coefficient Associated with Clinical Risk Scores for Prostate Cancers that Are Visible on 3-T MR Images?. Radiology, 2011, 258, 488-495.	3.6	372
521	Biomarker research in prostate cancerâ€"towards utility, not futility. Nature Reviews Urology, 2011, 8, 131-138.	1.9	35
522	Correlation between the preoperative serum prostate specific antigen, Gleason score, and clinical staging with pathological outcome following robot-assisted radical prostatectomy: An Indian experience. Indian Journal of Cancer, 2011, 48, 483.	0.2	2
523	Evaluation of the role of digital rectal examination and prostate specific antigen in diagnosis of prostate cancer. Journal of Clinical and Experimental Investigations, 2012, 3, .	0.1	0
524	The relationship between prostate size, patient age and prognostic factors in patients with prostate biopsy cancer detected. Turk Uroloji Dergisi, 2012, 38, 121-125.	0.4	0
526	Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent Retropubic Radical Prostatectomy. Advances in Urology, 2012, 2012, 1-7.	0.6	7
527	Clinical Versus Pathologic Staging for Prostate Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 364-368.	0.6	7
528	The Impact of Diabetes Mellitus on Survival in Men With Clinically Localized Prostate Cancer Treated With Permanent Interstitial Brachytherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 572-579.	0.6	9
529	Independent Diagnostic and Post-Treatment Prognostic Models for Prostate Cancer Demonstrate Significant Correlation with Disease Progression End Points. Journal of Endourology, 2012, 26, 451-456.	1.1	1
530	Prostate Anatomy and Prostate Cancer Screening, Diagnosis, Staging, and Prevention. , 2012, , 29-40.		0
531	Appropriate And Inappropriate Imaging Rates For Prostate Cancer Go Hand In Hand By Region, As If Set By Thermostat. Health Affairs, 2012, 31, 730-740.	2.5	35
532	Complications and Functional Results of Surgery for Locally Advanced Prostate Cancer. Advances in Urology, 2012, 2012, 1-8.	0.6	23
533	Update on prostate pathology. Pathology, 2012, 44, 391-406.	0.3	12
534	Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0â€ƒng/mL. BJU International, 2012, 110, E653-7.	1.3	10

#	Article	IF	Citations
535	Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer. Strahlentherapie Und Onkologie, 2012, 188, 1125-1132.	1.0	1
536	The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10Âng/ml. International Urology and Nephrology, 2012, 44, 1031-1038.	0.6	12
537	Phase I Trial of Pelvic Nodal Dose Escalation With Hypofractionated IMRT for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 184-190.	0.4	54
538	Distant Metastases Following Permanent Interstitial Brachytherapy for Patients With Clinically Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e225-e232.	0.4	8
539	20 Gy Versus 44 Gy of Supplemental External Beam Radiotherapy With Palladium-103 for Patients With Greater Risk Disease: Results of a Prospective Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2012, 82, e449-e455.	0.4	15
540	Twelve-Month Prostate-Specific Antigen Values and Perineural Invasion as Strong Independent Prognostic Variables of Long-Term Biochemical Outcome After Prostate Seed Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2012, 84, 962-967.	0.4	11
541	Impact of Concurrent Androgen Deprivation on Fiducial Marker Migration in External-beam Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, e7-e12.	0.4	9
542	The Population Level Prevalence and Correlates of Appropriate and Inappropriate Imaging to Stage Incident Prostate Cancer in the Medicare Population. Journal of Urology, 2012, 187, 97-102.	0.2	42
543	External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 584-589.	0.8	16
544	Decision curve analysis to compare 3 versions of Partin Tables to predict final pathologic stage. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 396-401.	0.8	7
545	Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy. Brachytherapy, 2012, 11, 250-255.	0.2	23
546	Prediction Tools in Surgical Oncology. Surgical Oncology Clinics of North America, 2012, 21, 439-447.	0.6	9
547	Development and Validation of a UK-Specific Prostate Cancer Staging Predictive Model: UK Prostate Cancer Tables. British Journal of Medical and Surgical Urology, 2012, 5, 224-235.	0.2	0
548	Gleason Pattern 5 is Frequently Underdiagnosed on Prostate Needle-core Biopsy. Urology, 2012, 79, 178-181.	0.5	20
549	Long-term Outcomes of Open Radical Retropubic Prostatectomy for Clinically Localized Prostate Cancer in the Prostate-specific Antigen Era. Urology, 2012, 79, 626-631.	0.5	40
550	Head to Head Comparison of Nomograms Predicting Probability of Lymph Node Invasion of Prostate Cancer in Patients Undergoing Extended Pelvic Lymph Node Dissection. Urology, 2012, 79, 546-551.	0.5	34
551	A New Scoring System for Predicting Stone-free Rate After Retrograde Intrarenal Surgery: The â€œResorlu-Unsal Stone Scoreâ€• Urology, 2012, 80, 512-518.	0.5	114
552	Editorial Comment. Urology, 2012, 80, 517.	0.5	0

#	Article	IF	Citations
553	Risk of Gleason Grade Inaccuracies in Prostate Cancer Patients Eligible for Active Surveillance. Urology, 2012, 80, 661-666.	0.5	49
554	Nuclear morphometry, nucleomics and prostate cancer progression. Asian Journal of Andrology, 2012, 14, 375-384.	0.8	25
555	Usefulness and predictive value of PSA density, adjusted by transition zone volume, in men with PSA levels between 2 and 4ng/ml. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2012, 36, 93-98.	0.2	3
556	Biochemical alterations associated with ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 110-118.	2.3	108
557	High-Dose 3D-CRT in the Radical and Postoperative Setting for Prostate Cancer. Analysis of Survival and Late Rectal and Urinary Toxicity. Tumori, 2012, 98, 337-343.	0.6	1
558	Cyr61 is regulated by cAMPâ€dependent protein kinase with serum levels correlating with prostate cancer aggressiveness. Prostate, 2012, 72, 966-976.	1.2	13
559	Radical prostatectomy: value of prostate MRI in surgical planning. Abdominal Imaging, 2012, 37, 664-674.	2.0	36
560	Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason grades than TRUS-guided biopsies in peripheral zone tumours. European Radiology, 2012, 22, 468-475.	2.3	104
561	The clinical impact of pathological review on selection the treatment modality for localized prostate cancer in candidates for brachytherapy monotherapy. World Journal of Urology, 2012, 30, 375-378.	1.2	6
563	Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy. BJU International, 2012, 109, 214-219.	1.3	19
564	Staging of prostate cancer. Histopathology, 2012, 60, 87-117.	1.6	114
565	Machine learning for improved pathological staging of prostate cancer: A performance comparison on a range of classifiers. Artificial Intelligence in Medicine, 2012, 55, 25-35.	3.8	34
566	Genetic variants associated with predisposition to prostate cancer and potential clinical implications. Journal of Internal Medicine, 2012, 271, 353-365.	2.7	80
567	An updated prostate cancer staging nomogram (<scp>P</scp>artin tables) based on cases from 2006 to 2011. BJU International, 2013, 111, 22-29.	1.3	323
568	Imaging Localised Prostate Carcinoma. , 2013, , 33-62.		0
569	Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review. BMC Cancer, 2013, 13, 131.	1.1	13
570	Reducing Morbidity of Pelvic and Retroperitoneal Lymphadenectomy. Current Urology Reports, 2013, 14, 488-495.	1.0	3
571	The role of National Institutes of Health category IV prostatitis in accurately staging the newly diagnosed prostate cancer. Irish Journal of Medical Science, 2013, 182, 463-467.	0.8	4

#	Article	IF	Citations
572	Role of pelvic phased array magnetic resonance imaging in staging of prostate cancer specifically in patients diagnosed with clinically locally advanced tumours by digital rectal examination. World Journal of Urology, 2013, 31, 881-886.	1.2	35
573	Randomised Controlled Trial Comparing Laparoscopic and Robot-assisted Radical Prostatectomy. European Urology, 2013, 63, 606-614.	0.9	173
575	Pelvic lymph node dissection for prostate cancer: Adherence and accuracy of the recent guidelines. International Journal of Urology, 2013, 20, 405-410.	0.5	21
576	Development of a nomogram for predicting the stoneâ€free rate after transurethral ureterolithotripsy using semiâ€rigid ureteroscope. International Journal of Urology, 2013, 20, 616-621.	0.5	28
577	Long-term outcomes of prostate cancer patients with Gleason pattern 5 treated with combined brachytherapy and external beam radiotherapy. Brachytherapy, 2013, 12, 408-414.	0.2	14
578	Factors associated with downgrading in patients with high grade prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 442-447.	0.8	9
579	Utility of Choline Positron Emission Tomography/Computed Tomography for Lymph Node Involvement Identification in Intermediate- to High-risk Prostate Cancer: A Systematic Literature Review and Meta-analysis. European Urology, 2013, 63, 1040-1048.	0.9	251
580	Prostate Volumes Derived From MRI and Volume-Adjusted Serum Prostate-Specific Antigen: Correlation With Gleason Score of Prostate Cancer. American Journal of Roentgenology, 2013, 201, 1041-1048.	1.0	31
582	Prostate Cancer: Shifting from Morphology to Biology. , 2013, , .		1
583	Imaging in Prostate Carcinoma. Hematology/Oncology Clinics of North America, 2013, 27, 1163-1187.	0.9	8
584	Evaluation of prediction models for the staging of prostate cancer. BMC Medical Informatics and Decision Making, 2013, 13, 126.	1.5	20
585	Pathological Correlation between Number of Biopsies and Radical Surgery: Does It Make a Difference to Final Pathology?. Current Urology, 2013, 7, 24-27.	0.4	0
586	Nodal disease assessment in pelvic malignancy. Imaging, 2013, 22, 20120016.	0.0	1
587	Fuzzy expert system for predicting pathological stage of prostate cancer. Expert Systems With Applications, 2013, 40, 466-470.	4.4	49
588	Prostate cancer: ESMO Consensus Conference Guidelines 2012. Annals of Oncology, 2013, 24, 1141-1162.	0.6	137
589	Gleason score 7 prostate cancer treated with interstitial brachytherapy with or without supplemental external beam radiation and androgen deprivation therapy: Is the primary pattern on needle biopsy prognostic?. Brachytherapy, 2013, 12, 14-18.	0.2	14
590	Posttreatment Prostate-Specific Antigen Surveillance After Primary Treatment of Prostate Cancer. Mayo Clinic Proceedings, 2013, 88, 307-308.	1.4	0
591	Positive Posterior Margin of Needle Biopsy Cores Is an Independent Predictor for Extracapsular Extension in Retropubic Radical Prostatectomy. Urology, 2013, 81, 986-991.	0.5	2

#	Article	IF	Citations
593	A Prospective Study of Transition From Laparoscopic to Robot-assisted Radical Prostatectomy: Quality of Life Outcomes After 36-Month Follow-up. Urology, 2013, 81, 781-786.	0.5	39
594	A Dosimetric Comparison of Tomotherapy and Volumetric Modulated Arc Therapy in the Treatment of High-Risk Prostate Cancer With Pelvic Nodal Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 549-554.	0.4	30
595	Biomarkers of Potential Therapeutic Value. , 2013, , 181-187.		0
596	External Validation of Preoperative Nomograms Predicting Biochemical Recurrence after Radical Prostatectomy. Japanese Journal of Clinical Oncology, 2013, 43, 1255-1260.	0.6	8
597	Comparison of body-array MRI and Partin tables for predicting extracapsular prostate cancer. Journal of Clinical Urology, 2013, 6, 50-54.	0.1	1
598	Permanent prostate brachytherapy extracapsular radiation dose distributions: analysis of a multi-institutional database. Journal of Contemporary Brachytherapy, 2013, 3, 117-121.	0.4	12
599	Comparison of Three Versions of Partin Tables to Predict Final Pathologic Stage in a Chinese Cohort: A Decision Curve Analysis. Urologia Internationalis, 2013, 91, 69-74.	0.6	4
600	Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study. Histopathology, 2013, 63, 574-579.	1.6	80
601	Is pelvic lymph node dissection required at radical prostatectomy for lowâ€risk prostate cancer?. International Journal of Urology, 2013, 20, 1092-1096.	0.5	18
602	Radiotherapy in the management of prostate cancer after radical prostatectomy. Future Oncology, 2013, 9, 669-679.	1.1	5
603	Interstitial Prostate Brachytherapy. , 2013, , .		1
604	Ability of prostate specific antigen to predict bone scan result in prostate cancer patients. Medical Journal of Indonesia, 2013, 13, 151.	0.2	0
605	The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era. Canadian Urological Association Journal, 2013, 7, 722.	0.3	17
606	Significance of Neoadjuvant Hormonal Therapy in Radical Retropubic Prostatectomy: A Retrospective Single-Surgeon Study. Yonsei Medical Journal, 2013, 54, 410.	0.9	1
607	The percentage of affected fragments in needle biopsy in the assessment of pathological staging of prostate cancer. Jornal Brasileiro De Patologia E Medicina Laboratorial, 2013, 49, 355-360.	0.3	0
608	Recommendations by Canadian urologists and radiation oncologists for the treatment of clinically localized prostate cancer. Canadian Urological Association Journal, 2013, 2, 197.	0.3	9
609	Biochip analysis of prostate cancer. Genetics and Molecular Research, 2014, 13, 152-159.	0.3	1
610	A role for STEAP2 in prostate cancer progression. Clinical and Experimental Metastasis, 2014, 31, 909-920.	1.7	48

#	Article	IF	Citations
611	External Validation of the European Association of Urology Recommendations for Pelvic Lymph Node Dissection in Patients Treated with Robot-Assisted Radical Prostatectomy. Journal of Endourology, 2014, 28, 416-423.	1.1	33
612	The effects of retropubic and perineal radical prostatectomy techniques on postoperative urinary continence after surgery: Results of 196 patients. Turk Uroloji Dergisi, 2014, 39, 147-152.	0.4	3
613	Impact of intraoperative MRI/TRUS fusion on dosimetric parameters in cT3a prostate cancer patients treated with high-dose-rate real-time brachytherapy. Journal of Contemporary Brachytherapy, 2014, 2, 154-160.	0.4	10
614	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Archives of Pathology and Laboratory Medicine, 2014, 138, 1387-1405.	1.2	117
615	Clinical Predictors and Recommendations for Staging Computed Tomography Scan Among Men With Prostate Cancer. Urology, 2014, 84, 1329-1334.	0.5	26
616	Editorial Comment. Urology, 2014, 84, 1334.	0.5	0
617	Multisector dosimetry in the immediate post-implant period: significant under dosage of the prostate base. Journal of Contemporary Brachytherapy, 2014, 1, 33-39.	0.4	7
618	Prostate cancer in deceased organ donors: A review. Transplantation Reviews, 2014, 28, 1-5.	1.2	13
619	Indication for and Extension of Pelvic Lymph Node Dissection During Robot-assisted Radical Prostatectomy: An Analysis of Five European Institutions. European Urology, 2014, 66, 635-643.	0.9	51
621	The role of elective pelvic radiotherapy in clinically node-negative prostate cancer: A systematic review. Radiotherapy and Oncology, 2014, 110, 45-54.	0.3	20
623	Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiation Oncology, 2014, 9, 44.	1.2	93
624	MR Imaging of the Prostate. Radiologic Clinics of North America, 2014, 52, 811-837.	0.9	29
625	Imaging in Clinical Oncology. , 2014, , .		2
626	Multiparametric Magnetic Resonance Imaging and Image-Guided Biopsy to Detect Seminal Vesicle Invasion by Prostate Cancer. Journal of Endourology, 2014, 28, 1283-1289.	1.1	45
627	Artificial neural network for predicting pathological stage of clinically localized prostate cancer in a Taiwanese population. Journal of the Chinese Medical Association, 2014, 77, 513-518.	0.6	22
628	Biomarkers in prostate cancer: new era and prospective. Medical Oncology, 2014, 31, 140.	1.2	19
629	Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literature. BMC Cancer, 2014, 14, 613.	1.1	5
630	Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1413-1419.	1.2	35

#	Article	IF	Citations
631	Seminal vesicle biopsies: an useful staging procedureâ€"exposure of seminal vesicle biopsies protocol and review of the literature. International Urology and Nephrology, 2014, 46, 297-302.	0.6	1
632	The cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer: A validation study on a Turkish patient population in different age categories. Kaohsiung Journal of Medical Sciences, 2014, 30, 545-550.	0.8	20
633	Defining prostate cancer risk after radical prostatectomy. European Journal of Surgical Oncology, 2014, 40, 496-504.	0.5	29
634	Preoperative prostate-specific antigen isoform p2PSAâ‰22.5pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1317-1326.	0.8	10
635	Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1292-1299.	0.8	80
636	Prostate malignancy grading using gland-related shape descriptors. Proceedings of SPIE, 2014, , .	0.8	0
638	Importance of prostate volume in the stratification of patients with intermediateâ€risk prostate cancer. International Journal of Urology, 2015, 22, 555-561.	0.5	16
639	<scp>miRNAs</scp> dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways. Journal of Pathology, 2015, 237, 226-237.	2.1	29
640	Stratification of brachytherapy-treated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts. Journal of Contemporary Brachytherapy, 2015, 6, 430-436.	0.4	9
641	Skeletal Metastasis of Unknown Primary Origin at the Initial Visit: A Retrospective Analysis of 286 Cases. PLoS ONE, 2015, 10, e0129428.	1.1	44
642	Outcomes of robot-assisted laparoscopic radical prostatectomy in high-risk prostate cancer patients: experience in 34 patients with oncologic and functional outcomes. Robotic Surgery (Auckland), 0, , 29.	1.3	2
643	Robotic radical prostatectomy in high-risk prostate cancer: current perspectives. Asian Journal of Andrology, 2015, 17, 908.	0.8	6
644	Role of anterior prostatic fat pad dissection for extended lymphadenectomy in prostate cancer: a non-randomized study of 100 patients. International Urology and Nephrology, 2015, 47, 959-964.	0.6	6
646	Influence of 11C-choline PET/CT on radiotherapy planning in prostate cancer. Reports of Practical Oncology and Radiotherapy, 2015, 20, 104-112.	0.3	8
647	ValidaciÃ³n de las tablas de Partin para cÃ¡ncer de prÃ³stata en poblaciÃ³n mexicana. Revista Mexicana De Urologia, 2015, 75, 126-131.	0.0	0
648	African-American Race Is a Predictor of Seminal Vesicle Invasion After Radical Prostatectomy. Clinical Genitourinary Cancer, 2015, 13, e65-e72.	0.9	10
649	Prognostic Utility of PET in Prostate Cancer. PET Clinics, 2015, 10, 255-263.	1.5	5
650	Utility of SPECT/CT scan for anatomical localization of pararectal and presacral sentinel nodes in prostate cancer. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 19-23.	0.1	3

#	Article	IF	Citations
651	Stereotactic Body Radiotherapy. , 2015, , .		3
652	TWIST overexpression predicts biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy. Scandinavian Journal of Urology, 2015, 49, 51-57.	0.6	11
653	Prospective assessment of urinary, gastrointestinal and sexual symptoms before, during and after image-guided volumetric modulated arc therapy for prostate cancer. Scandinavian Journal of Urology, 2015, 49, 58-69.	0.6	6
654	Reliability of sentinel node procedure for lymph node staging in prostate cancer patients at high risk for lymph node involvement. Acta OncolÃ³gica, 2015, 54, 896-902.	0.8	24
655	Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncology, The, 2015, 16, 274-283.	5.1	151
656	A urine-based methylation signature for risk stratification within low-risk prostate cancer. British Journal of Cancer, 2015, 112, 802-808.	2.9	16
657	Comparing CTVs for permanent prostate brachytherapy. Clinical and Translational Oncology, 2015, 17, 393-397.	1.2	0
659	Correlation of High Body Mass Index With More Advanced Localized Prostate Cancer at Radical Prostatectomy Is Not Reflected in PSA Level and PSA Density but Is Seen in PSA Mass. American Journal of Clinical Pathology, 2015, 144, 271-277.	0.4	15
660	Guideline-Discordant Use of Imaging During Work-Up of Newly Diagnosed Prostate Cancer. Journal of Oncology Practice, 2015, 11, e239-e246.	2.5	19
661	When to biopsy seminal vesicles. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2015, 39, 203-209.	0.2	3
662	Â¿CuÃ¡ndo biopsiar las vesÃculas seminales?. Actas UrolÃ³gicas EspaÃ±olas, 2015, 39, 203-209.	0.3	3
663	Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 244-251.	0.4	49
664	Could Machine Learning Improve the Prediction of Pelvic Nodal Status of Prostate Cancer Patients? Preliminary Results of a Pilot Study. Cancer Investigation, 2015, 33, 232-240.	0.6	4
665	MR Imagingâ€“Transrectal US Fusion for Targeted Prostate Biopsies: Implications for Diagnosis and Clinical Management. Radiographics, 2015, 35, 696-708.	1.4	69
666	The Role of Magnetic Resonance Image Guided Prostate Biopsy in Stratifying Men for Risk of Extracapsular Extension at Radical Prostatectomy. Journal of Urology, 2015, 194, 105-111.	0.2	56
667	Diffusion-weighted imaging of prostate cancer: effect of b-value distribution on repeatability and cancer characterization. Magnetic Resonance Imaging, 2015, 33, 1212-1218.	1.0	23
668	Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials. Brachytherapy, 2015, 14, 677-685.	0.2	21
670	Review by urological pathologists improves the accuracy of Gleason grading by general pathologists. BMC Urology, 2015, 15, 70.	0.6	21

#	Article	IF	Citations
673	Predictive Value of Magnetic Resonance Imaging Determined Tumor Contact Length for Extracapsular Extension of Prostate Cancer. Journal of Urology, 2015, 193, 466-472.	0.2	102
674	Results of tadalafil treatment in patients following an open nerve-sparing radical prostatectomy. Archivio Italiano Di Urologia Andrologia, 2016, 88, 4.	0.4	3
675	Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era. Canadian Urological Association Journal, 2016, 10, 17.	0.3	11
676	Preoperative Risk Assessment. , 2016, , 227-233.		0
677	Sentinel lymph Node Detection during Radical Prostatectomy for Prostate Cancer: Current Evidence and Results of Our Experience. Urologia, 2016, 83, 124-129.	0.3	0
678	Discoveries and application of prostate-specific antigen, and some proposals to optimize prostate cancer screening. Cancer Management and Research, 2016, 8, 45.	0.9	13
679	Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients. Prostate, 2016, 76, 1239-1256.	1.2	20
680	Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer. Abdominal Radiology, 2016, 41, 2209-2217.	1.0	15
681	International Society of Urological Pathology (ISUP) Grading of Prostate Cancer: Author's Reply. American Journal of Surgical Pathology, 2016, 40, 862-864.	2.1	9
682	Relaxation along fictitious field, diffusion-weighted imaging, and T₂mapping of prostate cancer: Prediction of cancer aggressiveness. Magnetic Resonance in Medicine, 2016, 75, 2130-2140.	1.9	15
683	Rentabilidad diagnÃ³stica y complicaciones de la linfadenectomÃa ampliada frente a la limitada asociada a prostatectomÃa radical. Actas UrolÃ³gicas EspaÃ±olas, 2016, 40, 75-81.	0.3	2
684	Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1718-1722.	0.8	1
685	Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer?. American Journal of Roentgenology, 2016, 207, 87-95.	1.0	36
686	Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncology, The, 2016, 17, 747-756.	5.1	317
687	RevisiÃ³n de biopsias de prÃ³stata en un centro de nivel iv de complejidad: Â¿realmente hay diferencias?. Urologia Colombiana, 2016, 25, 214-218.	0.0	2
688	Sexual Function After Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer: Results from the Randomized Phase III HYPRO Trial. Journal of Sexual Medicine, 2016, 13, 1695-1703.	0.3	8
689	Prostate cancer markers: An update. Biomedical Reports, 2016, 4, 263-268.	0.9	43
690	Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers. Future Oncology, 2016, 12, 2417-2430.	1.1	20

#	Article	IF	Citations
691	Questions and answers on prostate multiparameter magnetic resonance imaging: Everything a urologist should know. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2016, 40, 339-352.	0.2	1
692	Prospective assessment of the quality of life before, during and after image guided intensity modulated radiotherapy for prostate cancer. Radiation Oncology, 2016, 11, 117.	1.2	3
693	The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. Biomarkers in Cancer, 2016, 8s2, BIC.S31802.	3.6	70
694	Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, The, 2016, 17, 1061-1069.	5.1	385
695	Diagnostic yield and complications of extended lymphadenectomy versus limited lymphadenectomy combined with radical prostatectomy. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2016, 40, 75-81.	0.2	0
696	Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts. International Journal of Radiation Oncology Biology Physics, 2016, 95, 680-689.	0.4	79
697	Multiparametric prostate MRI: focus on T2-weighted imaging and role in staging of prostate cancer. Abdominal Radiology, 2016, 41, 831-843.	1.0	22
698	Rotating frame relaxation imaging of prostate cancer: Repeatability, cancer detection, and Gleason score prediction. Magnetic Resonance in Medicine, 2016, 75, 337-344.	1.9	16
699	Preguntas y respuestas sobre resonancia magnÃ©tica multiparamÃ©trica prostÃ¡tica: todo lo que el urÃ³logo debe conocer. Actas UrolÃ³gicas EspaÃ±olas, 2016, 40, 339-352.	0.3	1
700	Is supplemental external beam radiation therapy essential to maximize brachytherapy outcomes in patients with unfavorable intermediate-risk disease?. Brachytherapy, 2016, 15, 79-84.	0.2	14
701	Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncology, The, 2016, 17, 464-474.	5.1	242
702	Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database. World Journal of Urology, 2016, 34, 517-523.	1.2	31
704	Renal donors with prostate cancer, no longer a reason to decline. Transplantation Reviews, 2016, 30, 48-50.	1.2	5
705	Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, djw281.	3.0	5
706	Radiotherapy in the Management of Prostate Cancer. Medical Radiology, 2017, , 87-112.	0.0	0
707	Screening and Detection of Prostate Cancerâ€"Review of Literature and Current Perspective. Indian Journal of Surgical Oncology, 2017, 8, 160-168.	0.3	8
708	Functional Outcomes Following Nerve Sparing Prostatectomy Augmented with Seminal Vesicle Sparing Compared to Standard Nerve Sparing Prostatectomy: Results from a Randomized Controlled Trial. Journal of Urology, 2017, 198, 600-607.	0.2	16
711	Development and external validation of a biopsyâ€derived nomogram to predict risk of ipsilateral extraprostatic extension. BJU International, 2017, 120, 76-82.	1.3	23

#	Article	IF	Citations
712	Preoperative Predictors of Extraprostatic Extension of Prostate Cancer (pT3a) in a Contemporary Indian Cohort. Indian Journal of Surgical Oncology, 2017, 8, 331-336.	0.3	1
714	Association between protocadherin 8 promoter hypermethylation and the pathological status of prostate cancer. Oncology Letters, 2017, 14, 1657-1664.	0.8	12
715	Local Protocol Variations for Image Guided Radiation Therapy in the Multicenter Dutch Hypofractionation (HYPRO) Trial: Impact of Rectal Balloon and MRI Delineation on Anorectal Dose and Gastrointestinal Toxicity Levels. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1243-1252.	0.4	28
716	High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes. Radiotherapy and Oncology, 2017, 124, 49-55.	0.3	31
717	Evaluation of extracapsular extension in prostate cancer using qualitative and quantitative multiparametric MRI. Journal of Magnetic Resonance Imaging, 2017, 45, 1760-1770.	1.9	18
718	Significance of Gleason Score 7 With Tertiary Pattern 5 at Radical Prostatectomy. Urology, 2017, 100, 175-179.	0.5	13
719	Validation of prostateâ€specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries. Cancer, 2017, 123, 697-703.	2.0	27
720	Populationâ€Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients. Prostate, 2017, 77, 105-113.	1.2	21
721	Prediction of pathological stage based on clinical stage, serum prostateâ€specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. BJU International, 2017, 119, 676-683.	1.3	86
722	The Surgical Management of Prostate Cancer. Seminars in Oncology, 2017, 44, 347-357.	0.8	60
723	â€œResearching the Researchâ€•in Prostate Cancer: A Comparative Bibliometric Analysis of the Top 100 Cited Articles in the Field of Prostate Cancer. Current Urology, 2017, 11, 26-35.	0.4	8
724	Decision-making tools in prostate cancer: from risk grouping to nomograms. Minerva Urology and Nephrology, 2017, 69, 556-566.	1.3	10
725	The Influence of Serum Prostate-Specific Antigen on the Accuracy of Magnetic Resonance Imaging Targeted Biopsy versus Saturation Biopsy in Patients with Previous Negative Biopsy. BioMed Research International, 2017, 2017, 1-6.	0.9	3
726	Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial. Radiation Oncology, 2017, 12, 138.	1.2	14
728	Factores predictivos de recidiva bioquÃmica temprana, intermedia y tardÃa tras prostatectomÃa radical mÃnimamente invasiva en una cohorte unicÃ©ntrica con seguimiento medio de 8 aÃ±os. Actas UrolÃ³gicas EspaÃ±olas, 2018, 42, 516-523.	0.3	2
729	Follow-up Survey of Donor Candidates for Living Related Kidney Transplantation With Prostate Cancer. Transplantation Proceedings, 2018, 50, 2338-2341.	0.3	1
730	Clinical and Novel Biomarkers in the Management of Prostate Cancer. Current Treatment Options in Oncology, 2018, 19, 8.	1.3	16
731	Switching from laparoscopic radical prostatectomy to robot assisted laparoscopic prostatectomy: comparing oncological outcomes and complications. Scandinavian Journal of Urology, 2018, 52, 116-121.	0.6	9

#	Article	IF	Citations
732	Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making. Radiologic Clinics of North America, 2018, 56, 239-250.	0.9	13
733	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. Cancer Discovery, 2018, 8, 288-303.	7.7	107
734	Comparison of nomograms predicting lymph node invasion in patients undergoing radical prostatectomy for prostate cancer. Irish Journal of Medical Science, 2018, 187, 33-37.	0.8	5
735	Elevated preoperative neutrophilâ€“lymphocyte ratio predicts upgrading at radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2018, 21, 100-105.	2.0	16
736	Preoperative PROSTATE scoring system: a potential predictive tool for the risk of biochemical recurrence after radical prostatectomy. Cancer Management and Research, 2018, Volume 10, 4671-4677.	0.9	1
737	Introduction to Prostate Cancer. , 2018, , 567-571.		0
738	Pelvic Lymph Node Dissection for Prostate Cancer and Nomograms. , 2018, , 317-330.		0
739	Predictors of early, intermediate and late biochemical recurrence after minimally invasive radical prostatectomy in a single-center cohort with a mean follow-up of 8 years. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2018, 42, 516-523.	0.2	0
740	Development and External Validation of Nomograms To Predict Adverse Pathological Characteristics After Robotic Prostatectomy: Results of a Prospective, Multi-institutional, Nationwide series. European Urology Oncology, 2018, 1, 338-345.	2.6	9
741	Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP. Practical Radiation Oncology, 2018, 8, 445-451.	1.1	1
742	Autumn Royal and Ribier Grape Juice Extracts Reduced Viability and Metastatic Potential of Colon Cancer Cells. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-7.	0.5	12
743	Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making. Urologic Clinics of North America, 2018, 45, 455-466.	0.8	9
744	Diagnostic accuracy of multiparametric magnetic resonance imaging in detecting extracapsular extension in intermediate and high - risk prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 688-696.	0.7	21
746	Contemporary Approach to Gleason Grading of Prostate Cancer. , 2019, , 45-67.		0
747	Decision Support Systems in Prostate Cancer Treatment: An Overview. BioMed Research International, 2019, 2019, 1-10.	0.9	19
748	Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncology, The, 2019, 20, 1740-1749.	5.1	147
749	Apparent diffusion coefficient in extraprostatic extension of prostate cancer: a systematic review and diagnostic meta-analysis . Cancer Management and Research, 2019, Volume 11, 3125-3137.	0.9	8
750	Predicting side-specific prostate cancer extracapsular extension: a simple decision rule of PSA, biopsy, and MRI parameters. International Urology and Nephrology, 2019, 51, 1545-1552.	0.6	18

#	Article	IF	Citations
751	First live case of augmented reality robot-assisted radical prostatectomy from 3D magnetic resonance imaging reconstruction integrated with PRECE model (Predicting Extracapsular extension of prostate) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		4
752	Oncological safety of intrafascial nerve-sparing radical prostatectomy compared with conventional process: a pooled review and meta-regression analysis based on available studies. BMC Urology, 2019, 19, 41.	0.6	7
753	Is Extraprostatic Extension of Cancer Predictable? A Review of Predictive Tools and an External Validation Based on a Large and a Single Center Cohort of Prostate Cancer Patients. Urology, 2019, 129, 8-20.	0.5	26
754	Prostate health index density predicts aggressive pathological outcomes after radical prostatectomy in Taiwanese patients. Journal of the Chinese Medical Association, 2019, 82, 835-839.	0.6	8
755	Sensitivity and specificity of Briganti nomogram in Turkish patients undergoing radical prostatectomy and pelvic lymph node dissection. Aging Male, 2020, 23, 836-840.	0.9	3
756	Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups. European Urology Oncology, 2020, 3, 631-639.	2.6	4
757	Combination possibility and deep learning model as clinical decision-aided approach for prostate cancer. Health Informatics Journal, 2020, 26, 945-962.	1.1	10
758	Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and decipher genomic score. Journal of Magnetic Resonance Imaging, 2020, 51, 1075-1085.	1.9	24
759	Histologically Confirmed Diagnostic Efficacy of ¹⁸F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 710-715.	2.8	34
760	The evolution and resurgence of perineal prostatectomy in the robotic surgical era. World Journal of Urology, 2020, 38, 821-828.	1.2	25
761	Surgical management of high-risk, localized prostate cancer. Nature Reviews Urology, 2020, 17, 679-690.	1.9	20
762	Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer. JAMA Oncology, 2020, 6, 1793.	3.4	10
763	Extraprostatic extension in prostate cancer: primer for radiologists. Abdominal Radiology, 2020, 45, 4040-4051.	1.0	17
764	MRI/TRUS fusion vs. systematic biopsy: intra-patient comparison of diagnostic accuracy for prostate cancer using PI-RADS v2. Abdominal Radiology, 2020, 45, 2235-2243.	1.0	5
765	Prostate MRI: staging and decision-making. Abdominal Radiology, 2020, 45, 2143-2153.	1.0	8
766	Local Dose Effects for Late Gastrointestinal Toxicity After Hypofractionated and Conventionally Fractionated Modern Radiotherapy for Prostate Cancer in the HYPRO Trial. Frontiers in Oncology, 2020, 10, 469.	1.3	16
768	Prospect and adversity of artificial intelligence in urology. , 2021, , 309-337.		1
769	Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation. Cancers, 2021, 13, 435.	1.7	3

#	Article	IF	Citations
770	Association between incidental dose outside the prostate and tumor control after modern image-guided radiotherapy. Physics and Imaging in Radiation Oncology, 2021, 17, 25-31.	1.2	6
771	Head-to-Head Comparison of Two Nomograms Predicting Probability of Lymph Node Invasion in Prostate Cancer and the Therapeutic Impact of Higher Nomogram Threshold. Journal of Clinical Medicine, 2021, 10, 999.	1.0	8
772	Validation of the new STAR-CAP prognostic group staging system in prostate cancer patients treated with radiation therapy. World Journal of Urology, 2021, 39, 4127-4133.	1.2	3
773	Institute for Clinical and Economic Review. , 2021, , 112-141.		0
775	Patient reported toxicity and quality of life after hypofractionated high-dose intensity-modulated radiotherapy for intermediate- and high risk prostate cancer. Clinical and Translational Radiation Oncology, 2021, 29, 40-46.	0.9	4
777	Prostate Brachytherapy: Low Dose Rate. , 2013, , 719-738.		1
778	Prostate Cancer Markers. , 2004, , 85-128.		2
779	Nomograms for Prostate Cancer. , 2009, , 117-180.		1
780	Prostate Cancer Surveillance Counterpoint: USA. , 2013, , 411-420.		1
781	Focal Therapy: Prostate Hemiablation as the First Historical Treatment Model for Focal Therapy of Early Stage Prostate Cancer. , 2012, , 225-241.		1
782	Surgical Management of Carcinoma of the Prostate. , 2008, , 482-496.		1
784	Biomarkers for Cancer Diagnostics. , 2008, , 277-282.		4
786	MRI of the Male Pelvis and the Bladder. , 2005, , 371-424.		2
787	Cancer of the Prostate. , 2010, , 925-986.		2
788	Definitive Therapy for Localized Prostate Cancer. , 2012, , 2771-2788.e6.		2
789	Radical Retropubic and Perineal Prostatectomy. , 2012, , 2801-2829.e4.		8
790	Cyr61 is a potential prognostic marker for prostate cancer. Asian Journal of Andrology, 2012, 14, 405-408.	0.8	20
791	Gleason Score 7 Prostate Cancer on Needle Biopsy: Is the Prognostic Difference in Gleason Scores 4 3 and 3 4 Independent of the Number of Involved Cores?. Journal of Urology, 2002, , 2440-2442.	0.2	4

#	Article	IF	Citations
792	Percent Free Prostate Specific Antigen in the Total Prostate Specific Antigen 2 to 4 ng./ml. Range Does Not Substantially Increase the Number of Biopsies Needed to Detect Clinically Significant Prostate Cancer Compared to the 4 to 10 ng./ml. Range. Journal of Urology, 2002, , 504-508.	0.2	4
793	On Risk Estimation versus Risk Stratification in Early Prostate Cancer. PLoS Medicine, 2016, 13, e1002100.	3.9	5
794	A Novel MiRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy. PLoS ONE, 2015, 10, e0118745.	1.1	27
795	Association between Seminal Vesicle Invasion and Prostate Cancer Detection Location after Transrectal Systemic Biopsy among Men Who Underwent Radical Prostatectomy. PLoS ONE, 2016, 11, e0148690.	1.1	4
796	Clinical Nomograms to Predict Stone-Free Rates after Shock-Wave Lithotripsy: Development and Internal-Validation. PLoS ONE, 2016, 11, e0149333.	1.1	17
797	Prediction of Pathological Stage in Patients with Prostate Cancer: A Neuro-Fuzzy Model. PLoS ONE, 2016, 11, e0155856.	1.1	45
798	Pathology Review for Patients with Prostate Cancer Referred to the SCCA Proton Center. International Journal of Particle Therapy, 2015, 1, 878-883.	0.9	1
799	The pros and cons of prostate-specific antigen testing. Biomedical Reviews, 2014, 12, 57.	0.6	1
800	Analysis of risk factors of involvement of seminal vesicles in patients with prostate cancer undergoing radical prostatectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2004, 30, 472-478.	0.7	3
801	PBK/TOPK enhances aggressive phenotype in prostate cancer via Î²-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion. Oncotarget, 2015, 6, 15594-15609.	0.8	52
802	Is it necessary to cure prostate cancer when it is possible? (Understanding the role of prostate infl) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.3	1
803	Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome. Asian Pacific Journal of Cancer Prevention, 2018, 19, 229-236.	0.5	14
804	Reliability of the different versions of Partin tables in predicting extraprostatic extension of prostate cancer: a systematic review and meta-analysis. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 457-478.	3.9	6
805	Brachytherapy from the urologistâ€™s perspective. , 2005, , 126-139.		1
807	Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy. Ecancermedicalscience, 2019, 13, 934.	0.6	12
808	Undetectable Prostate-Specific Antigen Level Following Prostate Brachytherapy: An Apples-to-Apples Comparison with Radical Prostatectomy. UroToday International Journal, 2010, 03, .	0.1	1
809	Assessment of the performance of Partin's nomogram (2007) in contemporary Indian cohort. Indian Journal of Urology, 2016, 32, 199.	0.2	8
810	The sentinel node concept in prostate cancer: Present reality and future prospects. Indian Journal of Urology, 2008, 24, 451.	0.2	7

#	Article	IF	Citations
811	The factors that affect the prediction of lymph node metastasis in prostate cancer. Journal of Cancer Research and Therapeutics, 2018, 14, 1094-1098.	0.3	5
812	Estrogen receptor (Î± and Î²) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population. Asian Journal of Andrology, 2015, 17, 98.	0.8	14
813	Serum lipid profiles: novel biomarkers predicting advanced prostate cancer in patients receiving radical prostatectomy. Asian Journal of Andrology, 2015, 17, 239.	0.8	14
814	A comparative study of 68Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: An initial experience. World Journal of Nuclear Medicine, 2017, 16, 186-191.	0.3	61
815	Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of â€œregression to the meanâ€•using routine clinical features with correlating biochemical relapse rates. Asian Journal of Andrology, 2019, 21, 598.	0.8	11
816	Initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography/computed tomography: A first-stop-shop. World Journal of Nuclear Medicine, 2018, 17, 261-269.	0.3	12
817	Magnetic resonance imaging of localized prostate cancer: coming of age in the psa era. Diagnostic and Interventional Radiology, 2011, 18, 34-45.	0.7	26
818	Local staging of prostate cancer with MRI. Diagnostic and Interventional Radiology, 2011, 18, 365-73.	0.7	29
819	Vigencia actual de los nomogramas en la estadificaciÃ³n del cÃ¡ncer de prÃ³stata. Archivos Espanoles De Urologia, 2006, 59, .	0.1	2
820	The factors predicting upgrading of prostate cancer by using International Society for Urological Pathology (ISUP) 2014 Gleason grading system. Turkish Journal of Urology, 2019, 45, 36-41.	1.3	5
821	Nuclear and cytoplasmic expression of ErbB-4 in prostate cancer. International Journal of Biological Markers, 2007, 22, 181-185.	0.7	4
822	Current Perspectives on the Gleason Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2009, 133, 1810-1816.	1.2	40
823	Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean Men. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7123-7127.	0.5	3
824	Transrectal Ultrasound-Guided Prostate Brachytherapy. , 2003, , 119-154.		2
825	Nerve-sparing Radical Retropubic Prostatectomy. , 2003, , 135-147.		0
826	Permanent Seed Interstitial Prostate Brachytherapy. , 2003, , 163-170.		0
827	The Decision-making Process for Prostate Cancer. , 2003, , 231-252.		0
828	CTV for Lymphatics in Prostate Adenocarcinoma: an Anatomical Description and Clinical Discussion. Medical Radiology, 2004, , 145-156.	0.0	2

#	Article	IF	Citations
829	å‰ç«‹è…ºç™Œã®æ²»ç™‚. Juntendoì„ Igaku, 2004, 50, 254-258.	0.1	0
830	Prostate Brachytherapy. , 2004, , 357-372.		0
831	When to Refer a Patient With Prostate Cancer to a Medical Oncologist. , 2004, , 553-560.		0
832	Prostata. , 2004, , 227-258.		0
833	Total, Complexed, and Free PSA Forms and Human Glandular Kallikrein 2. , 2004, , 15-36.		0
834	Predicting Outcomes. , 2004, , 159-193.		0
835	Prior Surgery. , 2005, , 245-252.		0
836	Laparoscopic Radical Nephrectomy. , 2005, , 821-843.		0
842	The Art and Science of Risk Stratification in Localized Prostate Cancer. Seminars in Preventive and Alternative Medicine, 2007, 3, 101-105.	0.1	0
843	PrognÃ³stico de CÃ¢ncer de PrÃ³stata: Probabilidade e Possibilidade. TeMa, 2007, 8, .	0.1	1
844	Anatomic Foundations of Nerve Sparing in Radical Prostatectomy. , 2008, , 85-90.		0
845	Sentinel Lymph Node Biopsy in Prostatic Cancer. , 2008, , 151-165.		0
846	The Use of Imaging Modalities in the Evaluation and Treatment of Prostate Cancer. , 2008, , 9-25.		0
848	Contemporary TRUS-Guided Prostate Biopsy for Screening and Staging. , 2009, , 49-62.		2
849	Decision Aid Criteria and Artificial Neural Networks for Optimizing Prostate Cancer Risk Prediction. , 2009, , 181-193.		0
850	Prostate Cancer: A Pathological Perspective. , 2010, , 87-120.		0
851	Prostatakarzinom. , 2010, , 313-375.		0
852	Open Radical Retropubic Prostatectomy: Technique and Outcomes. , 2010, , 105-119.		0

#	Article	IF	Citations
853	What Are Some New Developments in Prostate Cancer Diagnosis?. Journal of the Korean Medical Association, 2010, 53, 107.	0.1	0
854	Biopsy, Diagnosis, and Staging of Prostate Cancer. , 2010, , 9-43.		0
856	Nomograms as Predictive Tools for Prostate Cancer Patients Who Had Radical Prostatectomy. Open Journal of Urology, 2011, 01, 37-47.	0.0	0
861	Contemporary Approach to Gleason Grading of Prostate Cancer. , 2012, , 41-55.		0
862	Early Experiences of Image Guided Prostate and Pelvic Nodal Irradiation With Intensity Modulated Radiation Treatment in Localized Prostate Cancer. World Journal of Oncology, 2012, 3, 16-22.	0.6	0
863	Radiation Therapy for Prostate Cancer. , 2012, , 2850-2872.e6.		0
864	Treatment of Locally Advanced Prostate Cancer. , 2012, , 2903-2920.e5.		5
865	Early Detection, Diagnosis, and Staging of Prostate Cancer. , 2012, , 2763-2770.e7.		2
866	Clinical State of the Rising PSA Value after Definitive Local Therapy. , 2012, , 2921-2933.e3.		0
868	Real Time Clinical Decision Support System. , 0, , .		3
870	External Beam Radiotherapy for Low-Risk Prostate Cancer. , 2013, , 709-717.		0
871	Natural History, Role of Biopsy, and Active Surveillance of Renal Masses. , 2013, , 119-141.		0
872	Focal Therapy of Prostate Cancer by Radiofrequency and Photodynamic Therapy. , 2013, , 727-751.		0
873	Molecular Markers for Patient Selection and Stratification: Personalized Prognostic Predictive Models. , 2013, , 213-219.		0
874	Introduction to Prostate Cancer. , 2014, , 553-557.		0
875	Prostatakarzinom. , 2014, , 513-676.		0
876	Prostatakarzinom. , 2014, , 219-262.		0
877	Qualidade de vida em pacientes submetidos Ã prostatectomia radical. Revista EletrÃ´nica De Enfermagem, 2014, 16, .	0.1	0

#	Article	IF	Citations
878	Relationship between BMI, PSA and Histopathological Tumor Grade in a Caucasian Population Affected by Prostate Cancer. Global Journal of Medical and Clinical Case Reports, 0, , 014-019.	0.0	0
880	Prostate Stereotactic Body Radiotherapyâ€"Methods, Rationale, Outcomes, and Future Directions. , 2015, , 195-224.		0
881	Biochemical recurrence risk factors in surgically treated high and very high-risk prostate tumors. Central European Journal of Urology, 2015, 68, 302-7.	0.2	3
882	Treatment of the Prostate Cancer. , 2015, , 29-55.		0
883	Does anterior prostatic fat tissue removed during robotic radical prostatectomy contain any lymph nodes?. Central European Journal of Urology, 2015, 68, 410-4.	0.2	5
884	Prostatakarzinom. , 2015, , 141-156.		0
885	Robotic Surgery in Prostate Cancer. , 2017, , 205-229.		0
886	Pathology of Prostate Cancer. , 2017, , 11-18.		0
887	Prostate Gland Pathology. , 2018, , 267-395.		0
888	Laparoscopic radical prostatectomy. Urology Herald, 2018, 6, 57-72.	0.1	3
889	Natural History, Role of Biopsy, and Active Surveillance of Renal Masses. , 2020, , 133-157.		0
890	A narrative review of pelvic lymph node dissection in prostate cancer. Translational Andrology and Urology, 2020, 9, 3049-3055.	0.6	9
891	MRI grading for the prediction of prostate cancer aggressiveness. European Radiology, 2022, 32, 2351-2359.	2.3	20
892	Prostate Disease in the Aging Male. , 2006, , 235-270.		0
894	Radiotherapy for the Treatment of Locally Advanced Prostate Cancer. , 2007, , 377-396.		0
895	Surgical Treatment of Prostate Cancer. , 2007, , 24-38.		0
896	Choices for Surgery. , 2007, 175, 163-178.		0
897	Staging of Prostate Cancer. , 2007, 175, 109-130.		0

#	Article	IF	Citations
899	Prostatakarzinom. , 2014, , 513-676.		0
900	Prostatakarzinom. , 2014, , 219-262.		0
901	Advances in brachytherapy. Reviews in Urology, 2004, 6 Suppl 4, S37-48.	0.9	6
902	Advances in prostate cancer treatment: highlights from the 2nd international prostate cancer congress, st. Thomas, u.s. Virgin islands, july 17-20, 2002. Reviews in Urology, 2003, 5, 111-7.	0.9	0
903	Neoadjuvant Therapy for Prostate Cancer: An Oncologist's Perspective. Reviews in Urology, 2003, 5 Suppl 3, S28-37.	0.9	7
904	The importance of pelvic lymph node dissection in men with clinically localized prostate cancer. Reviews in Urology, 2006, 8, 112-9.	0.9	16
905	Breast cancer clinical and translational research: analogies and implications for prostate cancer. Reviews in Urology, 2007, 9 Suppl 2, S28-39.	0.9	1
907	Does prostate specific antigen density correlates with aggressiveness of the prostate cancer?. Hippokratia, 2009, 13, 232-6.	0.3	3
908	Predictive models for newly diagnosed prostate cancer patients. Reviews in Urology, 2009, 11, 117-26.	0.9	21
909	Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials. Reviews in Urology, 2009, 11, 127-33.	0.9	50
910	A comparison of bladder neck preservation and bladder neck reconstruction for urinary incontinence after radical retro pubic prostatectomy. Journal of Research in Medical Sciences, 2014, 19, 1140-4.	0.4	4
912	Long-Term Outcomes of Dose-Escalated Hypofractionated Radiotherapy in Localized Prostate Cancer. Biology, 2022, 11, 435.	1.3	0
913	Which one is better for predicting extraprostatic extension on multiparametric MRI: ESUR score, Likert scale, tumor contact length, or EPE grade?. European Journal of Radiology, 2022, 149, 110228.	1.2	9
914	The role of pelvic lymphadenectomy in the treatment of prostate cancer. Urologie Pro Praxi, 2021, 22, 133-138.	0.0	0
917	The Role of Conservative Policies in the Treatment of Prostate Cancer. , 0, , 153-166.		0
918	High-dose 3D-CRT in the radical and postoperative setting for prostate cancer. Analysis of survival and late rectal and urinary toxicity. Tumori, 2012, 98, 337-43.	0.6	1
919	Contemporary Pathological Stage Distribution After Radical Prostatectomy in North American High-Risk Prostate Cancer Patients. Clinical Genitourinary Cancer, 2022, 20, e380-e389.	0.9	5
920	Integration of magnetic resonance imaging into prostate cancer nomograms. Therapeutic Advances in Urology, 2022, 14, 175628722210963.	0.9	0

#	Article	IF	Citations
921	Diagnostic performance of positron emission tomography combined with computed tomography with 18F-PSMA-1007 for detecting local recurrence of prostate cancer after radical prostatectomy. Proceedings of the National Academy of Sciences of Belarus, Medical Series, 2022, 19, 151-159.	0.2	0
922	Results of robotic radical prostatectomy in the hands of surgeons without previous laparoscopic radical prostatectomy experience. Turkish Journal of Medical Sciences, 0, , .	0.4	7
923	Increasing Immune Dysfunction is Associated with Increasing Matrix-Metalloproteinase-2 Expression and Predicts Biochemical Failure in Men with Bone Marrow Micro-Metastasis Positive Localized Prostate Cancer. Asian Pacific Journal of Cancer Prevention, 2022, 23, 2497-2505.	0.5	4
924	Prostate Cancer Screening and Biopsy. , 2022, , 101-115.		0
927	A Nomogram for Predicting Prostate Cancer with Lymph Node Involvement in Robot-Assisted Radical Prostatectomy Era: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group). Diagnostics, 2022, 12, 2545.	1.3	3
928	Local Experience of Endorectal Magnetic Resonance Imaging of Prostate with Correlation to Radical Prostatectomy Specimens. Annals of the Academy of Medicine, Singapore, 2008, 37, 40-43.	0.2	12
930	The impact of local staging of prostate cancer determined on MRI or DRE at time of radical prostatectomy on progression-free survival: A Will Rogers phenomenon. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 106.e9-106.e16.	0.8	3
931	Outcomes of Robotic Radical Prostatectomy in High-risk Prostate Cancer Patients: Experience in 60 Patients with Oncological and Functional Outcomes. European Medical Journal Urology, 0, , 56-59.	0.0	0
932	A Review of Modern Imaging Landscape for Prostate Cancer: A Comprehensive Clinical Guide. Journal of Clinical Medicine, 2023, 12, 1186.	1.0	1
933	Neoadjuvent androgen deprivation for seminal vesicle reduction: The optimal portion of seminal vesicle included in the high-dose CTV in localized prostate cancer radiotherapy. Radiation Medicine and Protection, 2023, 4, 43-47.	0.4	0
934	Robot-Assisted Laparoscopic Radical Prostatectomy: A Review of Technique and Outcomes. European Medical Journal Reproductive Health, 0, , 59-63.	1.0	0
936	Prostate Cancer Risk Analysis Using Artificial Neural Network. Lecture Notes in Networks and Systems, 2023, , 99-108.	0.5	0